



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 401/12, A61K 31/395, C07D 209/20, 213/89, 213/40, 213/56, 405/12, 417/12</p>	A1	<p>(11) International Publication Number: WO 98/07718</p> <p>(43) International Publication Date: 26 February 1998 (26.02.98)</p>		
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(21) International Application Number: PCT/US97/13871</p> <p>(22) International Filing Date: 6 August 1997 (06.08.97)</p> <p>(30) Priority Data: 60/024,323 22 August 1996 (22.08.96) US</p> <p>(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): HORWELL, David, Christopher [GB/GB]; 8 West Hill, Foxton, Cambridge CB2 6SZ (GB). PRITCHARD, Martyn, Clive [GB/GB]; The Maples, 9 Bury Close, St. Ives, Huntingdon, Cambridgeshire PE17 4WB (GB).</p> <p>(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.</p> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> </td> </tr> </table>			<p>(21) International Application Number: PCT/US97/13871</p> <p>(22) International Filing Date: 6 August 1997 (06.08.97)</p> <p>(30) Priority Data: 60/024,323 22 August 1996 (22.08.96) US</p> <p>(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): HORWELL, David, Christopher [GB/GB]; 8 West Hill, Foxton, Cambridge CB2 6SZ (GB). PRITCHARD, Martyn, Clive [GB/GB]; The Maples, 9 Bury Close, St. Ives, Huntingdon, Cambridgeshire PE17 4WB (GB).</p> <p>(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.</p>	<p>(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(21) International Application Number: PCT/US97/13871</p> <p>(22) International Filing Date: 6 August 1997 (06.08.97)</p> <p>(30) Priority Data: 60/024,323 22 August 1996 (22.08.96) US</p> <p>(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): HORWELL, David, Christopher [GB/GB]; 8 West Hill, Foxton, Cambridge CB2 6SZ (GB). PRITCHARD, Martyn, Clive [GB/GB]; The Maples, 9 Bury Close, St. Ives, Huntingdon, Cambridgeshire PE17 4WB (GB).</p> <p>(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.</p>	<p>(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>			
<p>(54) Title: NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS</p> <p>(57) Abstract</p> <p>Compounds of Formula (I) or a pharmaceutically acceptable salt thereof wherein Ar is phenyl or pyridyl unsubstituted or substituted. Ar¹ can be independently selected from Ar and can also include pyridyl-N-oxide, indolyl, imidazole, and pyridyl; R³ can be independently selected from Ar or is hydrogen, hydroxy, NMe₂, N-methyl-pyrrole, imidazole, tetrazole, thiazole (a), (b), (c) or (d), wherein Ar² is phenyl or pyridyl. The compounds of the instant invention are novel compounds which antagonize the bombesin receptors in mammals and are therefore effective in treating and/or preventing depression, psychoses, seasonal affective disorders, cancer, feeding disorders, gastrointestinal disorders, inflammatory bowel disease, sleep disorders, and memory impairment.</p> <div style="text-align: center; margin-top: 20px;"> <p style="text-align: right;">(I)</p> </div> <div style="display: flex; justify-content: space-around; margin-top: 20px;"> <div style="text-align: center;"> <p>(a)</p> </div> <div style="text-align: center;"> <p>(b)</p> </div> <div style="text-align: center;"> <p>(c)</p> </div> </div> <div style="text-align: center; margin-top: 20px;"> <p>(d)</p> </div>				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS

BACKGROUND OF THE INVENTION

Bombesin is a 14-amino acid peptide originally isolated from the skin of the European frog *Bombina bombina* (Anastasi A., et al., Experientia, 1971;27:166). It belongs to a class of peptides which share structural homology in their C-terminal decapeptide region (Dutta A.S., *Small Peptides; Chemistry, Biology, and Clinical Studies*, Chapter 2, pp 66-82). At present, two mammalian bombesin-like peptides have been identified (Battey J., et al., TINS, 1991;14:524), the decapeptide neuromedin B (NMB) and a 23-residue amino acid, gastrin-releasing peptide (GRP). Bombesin-like immunoreactivity detected in mammalian brain (Braun M., et al., Life. Sci., 1978;23:2721) and GI tract (Walsh J.H., et al., Fed. Proc. Fed. Am. Soc. Exp. Biol., 1979;38:2315) together with the more recent studies measuring mRNA levels in rat brain (Battey J., et al., TINS, 1991;14:524), point to the widespread distribution of both NMB and GRP in mammalian peripheral and central nervous systems.

NMB and GRP are believed to mediate a variety of biological actions via acting upon the corresponding bombesin receptors including their action as autocrine growth factors in human small cell lung carcinoma and other cancers (Taylor J.E., et al., Ann. N.Y. Acad. Sci., 1988;547:350; Rozengurt E., *Ibid.*, 277; Cuttitta F., et al., Nature, 1985;316:823; Kozacko M.F., et al., Proc. Natl. Acad. Sci. USA, 1996;93:2953), secretion of other neuropeptides and hormones (Ghatei M.A., et al., J. Clin. Endocrinol. Metab., 1982;54:980), contraction of smooth muscle (Erspamer V., et al., Pure Appl. Chem., 1973;35:463), behavioral effects (Kulkosky P.J., et al., Physiol. Behav., 1982;28:505; Gmerek D.E., et al., Peptides, 1983;4:907; Cowan A., Ann. N.Y. Acad. Sci., 1988;547:204), thermoregulation (Brown M.R., et al., Ann. N.Y. Acad. Sci., 1988;547:174), effects on satiety (Kirkham T.C., et al., Pharma. Biochem. Behav., 1995;52:101 and Ladenheim E.E., et al., Eur. J. Pharmacol., 1994;271:R7), regulation of circadian rhythms (Albers H., et al., J. Neurosci., 1991;11:846),

-2-

regulation of gastric acid secretion (Walsh J.H., Ann. Rev. Physiol., 1988;50:41) and gastrointestinal motility (see Lebacqz-Verheyden A., et al., in Handbook of Experimental Pharmacology, 1990;95 (Part II) and references therein), effects on locomotor activity and nociception (Pert A., et al., Brain Res., 1980;193:209), effects on memory (Flood J.F., et al., Brain Res., 1988;460:314), and interaction with 5HT-containing neurones (Pinnock R.D., et al., Brain Res., 1994;653:199 and Pinnock R.D., et al., J. Physiol., 1991;440:55).


Accordingly, compounds capable of antagonizing the effects of NMB and/or GRP at bombesin receptors will be useful in treating or preventing a variety of disorders including depression, psychoses, seasonal affective disorders, cancer, feeding disorders, gastrointestinal disorders including colitis, Crohn's disease and inflammatory bowel disease, sleeping disorders, and memory impairment.

SUMMARY OF THE INVENTION

This invention is for compounds which are bombesin receptor antagonists.

The compounds have proved to be antagonists of bombesin receptors.

The compounds of the invention are those of Formula I



or a pharmaceutically acceptable salt thereof wherein

Ar is phenyl or pyridyl unsubstituted or substituted by from 1 to 3 substituents selected from alkyl, halogen, alkoxy, nitro, amino, NH_2CH_2 -, cyano, CF_3 , $-\text{NHCONH}_2$, and CO_2R^1 ;

-3-

R^1 is hydrogen or straight, branched, or cyclic alkyl of from 1 to 7 carbon atoms;

R^8 is hydrogen or forms a ring with R^1 of from 3 to 7 carbon atoms;


5 R^2 is hydrogen or straight, branched, or cyclic alkyl of from 1 to 8 carbon atoms which can also contain 1 to 2 oxygen or nitrogen atoms;

R^9 is hydrogen or forms a ring of from 3 to 7 carbon atoms with R^2 which can contain an oxygen or nitrogen atom;


Ar^1 can be independently selected from Ar and can also include pyridyl-N-oxide, indolyl, imidazole, and pyridyl;

10 R^4 , R^5 , R^6 , and R^7 are each independently selected from hydrogen and methyl;

R^3 can be independently selected from Ar or is hydrogen, hydroxy, NMe_2 , N-methyl-pyrrole, imidazole, tetrazole, thiazole



15




DETAILED DESCRIPTION

The compounds of the invention are those of Formula I above.

Preferred compounds are those of Formula I

-4-



wherein

Ar is phenyl unsubstituted or substituted with 1 or 2 substituents selected from isopropyl, chloro, nitro, and cyano;

5 R⁴, R⁵, and R⁶ are hydrogen;

R⁷ is methyl or hydrogen;

R³ is 2-pyridyl or hydroxy; and

Ar¹ is indolyl, pyridyl, pyridyl-N-oxide, and imidazol.

Other preferred compounds are those of Formula I wherein

10 Ar is unsubstituted phenyl;


R¹ is cyclopentyl or tert-butyl;

R⁴ and R⁵ are hydrogen;

R⁷ is methyl;

R⁶ is hydrogen;

15 R³ is phenyl with two isopropyl substituents, unsubstituted phenyl, or



Ar¹ is indolyl.

Other preferred compounds are those of Formula I wherein

Ar is 2,6-diisopropyl-phenyl, 4-nitro-phenyl, and 4-cyano-phenyl;




20 R⁴, R⁵, and R⁶ are hydrogen;

R⁷ is methyl;

R² is hydrogen or cyclohexyl; and

-5-

R³ is hydroxyl,
pyridyl,



More preferred compounds are selected from

5 N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-propionamide;

N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-N-methyl-propionamide;

10 N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)-1-methyl-ureido]-3-(1H-indol-3-yl)-propionamide;

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-2-methyl-3-(1-oxy-pyridin-2-yl)-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide;

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-2-methyl-3-pyridin-2-yl-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide;

15 2-[3-(2-tert-Butyl-phenyl)-ureido]-N-cyclohexylmethyl-3-(1H-indol-3-yl)-2-methyl-propionamide;

-6-

N-Cyclohexylmethyl-2-[3-(2,6-dichloro-phenyl)ureido]-3-(1H-indol-3-yl)-
2-methyl-propionamide;

N-Cyclohexylmethyl-2-[3-(2,6-dimethoxy-phenyl)ureido]-3-(1H-indol-
3-yl)-2-methyl-propionamide;

5 N-Cyclohexylmethyl-2-[3-(2,6-dimethylamino-phenyl)-ureido]-3-(1H-
indol-3-yl)-2-methyl-propionamide;

[1-(Cyclohexylmethyl-carbamoyl)-2-(1H-indol-3-yl)-1-methyl-ethyl]-
carbamic acid 4-nitro-benzyl ester;

10 N-Cyclohexylmethyl-2-[3-(2,2-dimethyl-1-phenyl)propyl)-ureido]-3-(1H-
indol-3-yl)-2-methyl-propionamide;

{2-(1H-Indol-3-yl)-1-methyl-1-[(1-pyridin-2-yl-cyclohexylmethyl)-
carbamoyl]-ethyl}-carbamic acid 3-nitro-benzyl ester;

N-(2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(1H-indol-3-yl)-2-methyl-
2-[3-(1-phenyl-cyclopentylmethyl)-ureido]-propionamide;

15 (S)-N-(2,6-Diisopropyl-phenyl)-2-[3-(2,2-dimethyl-1-phenyl-propyl)-
ureido]-3-(1H-indol-3-yl)-propionamide;

(R)-N-(2,6-Diisopropyl-phenyl)-2-[3-(2,2-dimethyl-1-phenyl-propyl)-
ureido]-3-(1H-indol-3-yl)-propionamide;

20 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-N-(2,2-dimethyl-4-phenyl-
[1,3]dioxan-4-yl)-3-(1H-indol-3-yl)-2-methyl-propionamide;

N-Cyclohexyl-2-[3-(2,6-diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-
2-methyl-propionamide;

N-(2-Cyclohexyl-ethyl)-2-[3-(2,6-diisopropyl-phenyl)-ureido]-3-(1H-indol-
3-yl)-2-methyl-propionamide;

25 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-
propionamide;

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-
(3-methyl-butyl)-propionamide;

30 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-
(3-phenyl-propyl)-propionamide;

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-
(1,2,3,4-tetrahydro-naphthalen-1-yl)-propionamide;

-7-

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-(2-phenyl-cyclohexyl)-propionamide;

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-N-indan-1-yl-3-(1H-indol-3-yl)-2-methyl-propionamide;

5 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-N-(1-hydroxy-cyclohexylmethyl)-3-(1H-indol-3-yl)-2-methyl-propionamide;

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide; and

10 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl)-propionamide.

The compounds of the invention include solvates, hydrates, pharmaceutically acceptable salts, and polymorphs (different crystalline lattice descriptors) of the compounds of Formula I.

15 Pharmaceutical compounds of compounds of the invention are also covered by the instant invention.

Method of using the compounds of the instant invention are antagonizing the effect of neuromedin B and/or gastrin-releasing peptide at bombesin receptors. Other treatments are depressing seasonal affective disorders, feeding disorders, gastrointestinal disorders, sleep disorders, memory impairment, psychoses
20 treatment, and cancer treatment, for example, treatment of small cell lung cancers.

The compounds of the invention are those for Formula I and the pharmaceutically salts thereof. All stereoisomers of the compounds are included in the scope of the invention.

25 Prodrugs of the above are also contemplated such as would occur to one skilled in the art, see Bundgaard, et al., Acta Pharm. Suec., 1987;24:233-246.

The alkyl groups contemplated by the invention include straight, branched, or cyclic carbon chains of from 1 to 8 carbon atoms except where specifically stated otherwise. Representative groups are methyl ethyl, propyl, isopropyl, n-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, 2-methylhexyl, n-pentyl,
30 1-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, n-hexyl, and the like.

-8-

The cycloalkyl groups contemplated by the invention comprise those having 3 to 7 carbon atoms. They may be substituted with from 1 to 3 groups selected from halogens, nitro, alkyl, and alkoxy.

5 The alkoxy groups contemplated by the invention comprise both straight and branched carbon chains of from 1 to 6 carbon atoms unless otherwise stated. Representative groups are methoxyl, ethoxy, propoxy, i-propoxy, t-butoxy, and hexoxy.

The term "halogen" is intended to include fluorine, chlorine, bromine, and iodine.

10 The term "Ar" is intended to include substituted or unsubstituted phenyl. The substituents include one or more substituents such as halogens, nitro, alkyl, alkoxy, and others as specified or as would occur to one skilled in the art.

The term "amine" is free amino, alkylated amines, and acylated amines.

15 The compounds of the instant invention are highly selective antagonists of bombesin receptors.

For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.

20 A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active component is mixed with 25 the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

For preparing suppository preparations, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous 30 mixture is then poured into convenient sized molds and allowed to cool and solidify.

The powders and tablets preferably contain 5% to about 70% of the active component. Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.

5 The compounds of the present invention can have multiple chiral centers in the above Formula I depending on their structures. In particular, the compounds of the present invention may exist as diastereomers, mixtures of diastereomers, or as the mixed or the individual optical enantiomers. The present invention contemplates all such forms of the compounds. The mixtures of diastereomers are typically obtained as a result of the reactions described more fully below.

10 Individual diastereomers may be separated from mixtures of the diastereomers by conventional techniques such as column chromatography or repetitive recrystallizations. Individual enantiomers may be separated by conventional methods well known in the art such as conversion to a salt with an optically active compound, followed by separation by chromatography or recrystallization and
15 reconversion to the nonsalt form.

 Where it is appropriate to form a salt, the pharmaceutically acceptable salts are acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium acetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate,
20 estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycoloylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate/diphosphate, polygalacturonate, salicylate,
25 stearate, subacetate, succinate, sulfate, tannate, tartrate, theoclate, triethiodide, benzathine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc.

 Cyclodextrin is one suitable inclusion in a pharmaceutical preparation.

 The term "preparation" is intended to include the formulation of the active
30 component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it. Similarly, cachets are included.

-10-

Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

Liquid form preparations include solutions, suspensions, and emulsions. Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration. Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.

Preferably the pharmaceutical preparation is in unit dosage form. In such form, the preparation is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.

The compounds of the invention have been evaluated in receptor binding assays which measure the affinity of the novel compounds in a cloned human NMB-preferring receptor (BB₁) assay and in a cloned human GRP-preferring receptor (BB₂) assay.

Protocol for Binding Assays

CHO-K1 cells stably expressing cloned human NMB and GRP receptors were routinely grown in Ham's F12 culture medium supplemented with 10% foetal calf serum and 2 mM glutamine. For binding experiments, cells were harvested by trypsinization, and stored frozen at -70°C in Ham's F12 culture medium containing 5% DMSO until required. On the day of use, cells were thawed rapidly, diluted

-11-

with an excess of culture medium, and centrifuged for 5 minutes at 2000 g. Cells were resuspended in 50 mM Tris-HCl assay buffer (pH 7.4 at 21°C, containing 0.02% BSA, 40 µg/mL bacitracin, 2 µg/mL chymostatin, 4 µg/mL leupeptin, and 2 µM phosphoramidon), counted, and polytroned (setting 5, 10 sec) before centrifuging for 10 minutes at 28,000 g. The final pellet was resuspended in assay buffer to a final cell concentration of 1.5×10^5 /mL. For binding assays, 200 µL aliquots of membranes were incubated with [125 I][Tyr⁴]bombesin (<0.1 nM) in the presence and absence of test compounds (final assay volume 250 µL) for 60 minutes and 90 minutes for NMB and GRP receptors, respectively. Nonspecific binding was defined by 1 µM bombesin. Assays were terminated by rapid filtration under vacuum onto Whatman GF/C filters presoaked in 0.2% PEI for >2 hours, and washed 50 mM Tris-HCl (pH 6.9 at 21°C; 6 × 1 mL). Radioactivity bound was determined using a gamma counter. See Table 1.

The compounds of the invention have been tested in *in vitro* functional assays using cloned human NMB-preferring receptors expressed in CHO cells.

Protocols for functional assays:

1. Measurement of intracellular calcium levels

Culture of Chinese hamster ovary cells

Chinese hamster ovary cells were routinely grown as monolayers in Ham's F12 nutrient mixture supplemented with 10% FBS and 2 mM glutamine, and maintained at 37°C under 5% CO₂. Cells were passaged every 3 to 4 days. At each passaging, cells were seeded at a density of 3 to 6 million per 175 cm² flask. For the imaging experiments, cells were plated out onto glass coverslips at a density of 5 to 10,000/cm² and usually used within 2 to 3 days after plating.

[Ca²⁺] Studies in single cells

Plated cells were incubated with 2 µM Fura-2-AM for between 45 and 120 minutes at 25°C to 29°C. This procedure loaded the cells with the dye which was hydrolysed to the free acid form inside the intact cells. Single coverslips were then mounted in a chamber on top of an inverted fluorescence microscope and perfused with a Krebs-Hepes assay buffer (composition in mM: NaCl 118,

-12-

KCl 4.7, MgSO₄ 1.2, CaCl₂ 1.2, KH₂PO₄ 1.2, Hepes 10, glucose 11, pH 7.2 at 37°C) {332}.

Measurements of [Ca²⁺]_i in individual cells were made from the fluorescence ratio (excitations 340/380 nM, emission >510 nM for Fura-2) using a specially designed filter wheel assembly, CCD camera or photomultiplier tubes, and specially designed suites of software (MAGICAL OR phocal, Applied Imaging, Sunderland, UK) which samples emission following excitation at different wavelengths at regular intervals. The [Ca²⁺]_i could be calculated from a calibration curve using the equation $[Ca^{2+}] = K_d \cdot \beta \cdot ((R - R_{min}) / (R_{max} - R))$ where R_{max}, R_{min}, and R were, respectively, the maximum ratio, minimum ratio, and measured ratio at lower λ/upperλ. R_{max} (14.5), R_{min} (0.75), and β (8.51) were determined from free standing solutions of 2 mM and zero [Ca²⁺]_o (+1 mM EGTA) in Hepes buffer solution as previously described {458, 457}. These values did not vary significantly from day to day. The data was displayed as ratio values of emission after excitation at the lowerλ and upperλ (ie, 340/380 nM) due to the uncertainties in calculating cytosolic [Ca²⁺] from a calibration curve determined in free standing solutions. The relative concentration of Fura-2 inside cells over the course of an experiment was monitored by measuring emission after excitation at the dye's isobestic point (360 nM).

2. Measurement of extracellular acidification (CYTOSENSOR)

The Cytosensor Microphysiometer (Molecular Devices Corp., California, USA) has been demonstrated to measure the activity of isolated cells in terms of their rate of production of hydrogen ions. This acidification rate is detected as a change in potential across a silicon light addressable sensor, during periods of media cessation (McConnell, et al., 1992).

CHO-NMB Cells seeded on polycarbonate microporous capsule cups were placed in sensor chambers at 37°C inside the microphysiometer, and maintained by a flow of nonbuffering Ham's F12 nutrient media (growth media without NaHCO₃, pH 7.3-7.4) at approximately 120 μL/min. The flow was halted for 22 seconds at

-13-

the end of each 2 minute repeated cycle, and the rate of acidification (μ volts/sec) measured for 15 seconds during that period.

Agonists were introduced sequentially every 28 to 30 minutes to the perfusing media, 20 seconds before flow-off periods, and removed after two rate measurements via the automatic valve-switch.

The effects of various antagonists were determined after continuous perfusion 30 minutes prior to, and throughout the application of agonists. All agents were applied at the working pH of the media.

-14-

TABLE 1. Human NMB and GRP Receptor Binding Affinities

Example No.	NMB K_i (nM)	GRP K_i (nM)
11	103	IA
7	487	IA
24	413	IA
10	758	1460
19	3	762
22	35	589
20	33	IA
21	20	2550
23	16	5360
17	3310	2940
12	0.7	60
14	0.15	19
16	3	140
15	2	165
13	0.3	38
8	3	450
9	3.3	1130
18	25	IA
4	215	IA
5	942	IA
25	95	IA
2	14	IA
6	783	IA
1	5	IA
3	130	IA
26	0.25	29
27	0.15	1.0
28	0.81	79
29	10	IA
31	0.17	21
32	0.17	20

* IA is defined as those compounds which bind with lower than 10 micromolar affinity at the receptor.

-15-

TABLE 2. In Vitro Functional Activity of Compounds at NMB-Preferring Receptor (BB,1)

Example No.	[Ca ²⁺] _i Mobilization KE (nM)	Acidification Response appKB
2	--	54.3 (2.5-152.4)
1	18 (10-33)	7.6 (5.3-110)
14	1.2	1.0

General synthetic schemes for compounds of the invention follow.

DESCRIPTION OF SYNTHETIC SCHEMES

Scheme I describes the synthesis of C-terminal derivatives

- 5 Examples 1 through 6. Intermediate I is prepared by the addition of 2,6-diisopropyl phenyl isocyanate to α -methyl Trp in DMF at 100°C. Coupling of Intermediate I to a selection of amines using HBTU and DIPEA in DMF furnished Examples 1 through 6.

- 10 Scheme II highlights the synthesis of Example 7. Addition of 2,6-diisopropyl phenyl isocyanate to (RS)-tryptophan in DMF at 100°C provided Intermediate IV. This was then coupled to N-methyl cyclohexyl methyl amine using HBTU and DIPEA in DMF to give Example 7.

- 15 In Scheme III the intermediate acid V is prepared following the addition of p-nitrophenylisocyanate to (S)- α -methyl tryptophan in DMF at 60°C. Subsequent coupling of the intermediate acid V to cyclohexyl methyl amine and cyclohexan-1-ol methyl amine using HBTU and DIPEA in DMF yielded Examples 8 and 9, respectively.

Scheme IV outlines the preparation of Example 10. Initial addition of 2,6-diisopropyl phenyl isocyanate to (RS)-N-methyl tryptophan in DMF at 50°C

-16-

furnished the intermediate acid VI which was subsequently coupled to cyclohexyl methyl amine to provide Example 10.

In Scheme V the intermediate acid VII is prepared following the addition of Boc₂O to (S)- α -methyl tryptophan in dioxan/water in the presence of NaHCO₃.

5 Coupling of this intermediate to either cyclohexyl methyl amine or 1-(2-pyridyl) 1-aminomethyl cyclohexane (Intermediate II) in the presence of either HBTU, DIPEA, or DCC, PFP yielded the required Intermediate VIII. Deprotection of the Boc group using TFA in CH₂Cl₂ followed by coupling of the revealed amine to a selection of isocyanates in THF provided Examples 11 through 17.

10 Scheme VI describes the preparation of Example 18. Intermediate X is generated by adding Boc₂O in dioxan/water in the presence of NaHCO₃ to (S)- α -methyl tryptophan. Coupling of the free carboxylic acid in Intermediate X to 2,6-diisopropyl phenyl amine using HBTU and DIPEA in DMF yielded Intermediate XI. Subsequent removal of the Boc protecting group using TFA in
15 CH₂Cl₂ followed by reaction of the revealed amine with (RS)- α -t-butyl benzyl isocyanate in THF furnished Example 18.

In Scheme VII the intermediate acid XIII is prepared via the addition of 2,6-diisopropyl phenyl isocyanate to the required (RS)- α -methyl amino acid in DMF at 60°C. This intermediate is then coupled to 1-(2-pyridyl)-1-aminomethyl
20 cyclohexane (Intermediate II) using HBTU and DIPEA in DMF to yield Examples 19 through 21. Catalytic hydrogenation of Example 19 furnished Example 22.

Scheme VIII outlines the preparation of Example 23. (RS)-N-trityl-histidine was reacted with 2,6-diisopropyl-phenylisocyanate in DMF at 60°C to provide
25 Intermediate XIV. This acid was then coupled to 1-(2-pyridyl)-1-aminomethyl cyclohexane (Intermediate II) using HBTU and DIPEA in DMF to give Intermediate XV which was subsequently reacted with formic acid in CH₂Cl₂ to provide Example 23.

The synthesis of Example 24 is outlined in Scheme IX. Reacting
30 p-nitrophenyl chloroformate with (RS)- α -methyl tryptophan methyl ester provided the reactive Intermediate XVI which was then added to 2,6-diisopropylphenyl-N-

-17-

methyl amine in toluene to yield Intermediate XVII. Hydrolysis of the methyl ester using LiOH in MeOH/water gave Intermediate XVIII which was then coupled with cyclohexyl methyl amine using HBTU and DIPEA in DMF to give Example 24.


5 In Scheme X Intermediate XIX is prepared by adding the acetone of (S)-phenyl serinol to (RS)-N-Boc- α -methyl tryptophan using DCC and HOBT in CH_2Cl_2 . Subsequent removal of the N-Boc protecting group using HCl gas in Et_2O gave Intermediate XX which was then reacted with 2,6-diisopropyl phenyl isocyanate in EtOAc to give Example 25 after column chromatography.

10 Intermediate II was prepared after initial alkylation of pyridine-2-acetonitrile with 1,5-dibromopentane followed by reduction of the nitrile with Raney nickel.

Intermediate III was prepared by initial displacement of the alcohol in 2-phenyl cyclohexan-1-ol with azide via the use of DEAD, PPh_3 , and $(\text{PhO})_2\text{PON}_3$ in THF followed by catalytic reduction of the azide to give the amine
15 Intermediate III.

-18-






SCHEME 1



Reagents and Conditions:

- i) 2,6-diisopropylphenylisocyanate, triethylamine, DMF, 100°C;
ii) HBTU, R, DIPEA, DMF, 20°C

Table for Scheme 1

Example No.	*	R
1	S	 II
2	R	
3	R	
4	RS	
5	RS	NHPh
6	R	 III

-20-


Synthesis of Examples 1-6Step 1

To a stirred solution of α -methyl-tryptophan (1.0 g, 4.6 mmol) in DMF (50 mL) was added 2,6-diisopropyl phenyl isocyanate (1.0 g, 5 mmol) followed by triethylamine (1.4 g, 14 mmol), and the mixture was heated to 100°C for 1 hour. The reaction mixture was allowed to cool to room temperature and was taken up in EtOAc, washed with 1N HCl, brine, and dried (MgSO₄). The solvents were removed *in vacuo*, and the residue was triturated with ether to yield intermediate I as a white solid (1.38 g, 71%).

¹H NMR (DMSO): δ 1.15 (12H, br, 4 \times CH₃(iPr)), 1.46 (3H, s, α CH₃), 3.26 (3H, br, 2 \times CH(iPr), CHH indole), 3.41 (1H, d, 14.4 Hz, CHH indole), 6.32 (1H, br s, urea NH), 6.96-7.39 (7H, br m, 3 \times CH (Ph), indole H-2, H-5, H-6, H-7), 7.56 (2H, br, indole H-4, benzylic urea NH), 10.96 (1H, br, indole NH), 12.59 (1H, br, acid OH);

IR (film): 3357, 2959, 1704, 1657, 1620, 1526, and 1456 cm⁻¹; MS m/e (CI) 422 (M⁺ + H) (4%) 204 (100%); Analysis C₂₅H₃₁N₃O₃·0.25 H₂O, C, H, N; mp 194-195°C.

EXAMPLE 1



-21-

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-
2-methyl-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide

To a stirred solution of the acid (I) (674 mg, 1.6 mmol) in DMF (80 mL) was added 2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyl uranium
 5 hexafluorophosphate (HBTU) (607 mg, 1.6 mmol) followed by diisopropyl ethyl amine (620 mg, 4.8 mmol), and the mixture was stirred at room temperature for 5 minutes. Amine II (304 mg, 1.6 mmol) was added to the solution which was stirred for a further 2 hours. The reaction mixture was taken up in EtOAc and washed with NaHCO₃ (aq), brine, dried (MgSO₄), and concentrated *in vacuo*. The
 10 residue was purified on reverse phase silica eluting with a gradient of MeOH/H₂O 50% to 100% to give Example 1 as a white solid (696 mg, 73%).

¹H NMR (CDCl₃): δ 0.75 and 0.88 (6H, 2 × br d, (CH₃)₂CH), 1.03 (6H, br d, (CH₃)₂CH), 1.22-1.64 (8H, m, cyclohexyl), 1.64 (3H, s, αCH₃), 2.09-2.13 (2H, m, cyclohexyl), 2.97-3.04 (3H, m, (CH₃)₂CH × 2, CHH indole), 3.22 (1H, d,


15 14.65 Hz, CHH indole), 3.38-3.39 (2H, m, CNHCH₂), 4.94 (1H, br s,

20 PhNHCNH), 5.44 (1H, br s, PhNH), 6.34 (1H, brs, NH amide), 6.93-7.00 (2H, m, 2ArH), 7.03-7.11 (4H, m, 4ArH), 7.22 (1H, d, 8.06 Hz, ArH), 7.26-7.31 (2H, m, 2ArH), 7.36 (1H, d, 8.06 Hz, ArH), 7.633 and 7.63 (1H, dt, 7.60 Hz, ArH), 7.73 (1H, br s, indole NH), 8.54 (1H, d, 3.17 Hz, ArH);

IR (film): 3291.0, 2955.0, 2870.0, 1652.0, 1532.0, 1457.0, and 742.0 cm⁻¹; MS
 25 m/e (APCI): 594.7 (M⁺ + H); Analysis C₃₇H₄₇N₅O₂, C, H, N; mp 116-117°C; HPLC R.T. = 12.88, C¹⁸ reverse phase, 40% to 100% MeCN:TFA/H₂O:TFA.

-22-

EXAMPLE 2



2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-

2-methyl-N-(1,2,3,4-tetrahydro-naphthalen-1-yl)-propionamide

5 Example 2 was prepared as for Scheme 1 using 1,2,3,4-tetrahydro-1-naphthyl amine(s).

Example 2 was isolated in 24% yield.

¹H NMR (CDCl₃): δ 0.43-0.52 (3H, br d, CH₃CH), 0.90-0.94 (3H, br d, CH₃CH),
0.98 and 1.07 (6H, 2 × d, 6.59 and 6.11 Hz, (CH₃)₂CH), 1.70 (3H, s, αCH₃),
10 1.78-1.84 (3H, m, CHCHHCH₂tetralin), 1.87-2.04 (1H, m, CH₂CHHtetralin),
2.69-2.91 (3H, m, (CH₃)₂CH, PhCH₂), 2.89 (1H, d, 14.65 Hz, CHH indole),
3.06-3.15 (1H, m, (CH₃)₂CH), 3.47 (1H, d, 14.40 Hz, CHH indole), 4.75 (1H, br s,

15 $\begin{array}{c} \text{O} \\ \parallel \\ \text{PhNHC NH} \end{array}$), 5.01-5.06 (1H, m, CHN CH), $\begin{array}{c} \text{O} \\ \parallel \\ \text{CHN CH} \end{array}$), 5.30 (1H, br s, $\begin{array}{c} \text{O} \\ \parallel \\ \text{PhNH CNH} \end{array}$), 6.28 (1H, br s, NH amide), 6.63 (1H, br d, 7.57 Hz, ArH), 6.71 (1H, br d, 7.81 Hz, ArH), 6.91 (1H, t, 7.82 Hz, ArH), 6.98 (1H, t, 7.32 Hz, ArH), 7.04 (2H, t, 6.84 Hz, ArH), 7.09-7.16 (2H, m, 2ArH), 7.22-7.37 (3H, m, 3ArH), 7.39 (1H, d, 8.3 Hz, ArH), 7.77 (1H, br s, indole NH);


20 IR (film): 3291.0, 2962.0, 1674.0, 1651.6, 1506.0, 1456.0, and 737.0 cm⁻¹; MS m/e (APCI) 551.5 (M+H⁺);

-23-

Analysis $C_{35}H_{42}N_4O_2$, C, H, N; $\alpha^D = -45.33$ (MeOH, $c = 0.075$ g, 100 mL^{-1});
 mp 210-212°C; HPLC R.T. = 17.90, C^{18} reverse phase, 40% to 100%
 MeCN:TFA/H₂O:TFA.

EXAMPLE 3

5



2-[3-(2,6-Diisopropyl-phenyl)-ureido]-N-indan-1-yl-3-(1H-indol-3-yl)-2-methyl-propionamide

Example 3 was prepared as for Scheme 1 using S-(+)-1-aminoindone.

Example 3 was isolated in 40.5% yield.

10

^1H NMR (CDCl_3): δ 0.55 (3H, br s, CH_3CH), 0.94 (3H, br d, 5.62 Hz, CH_3CH),
 0.99 (3H, br d, 6.35 Hz, CH_3CH), 1.07 (3H, br d, 6.10 Hz, CH_3CH), 1.70 (3H, s,

15

αCH_3), 1.71-1.86 (1H, m, CNHCHCHH), 2.53-2.61 (1H, m, CNHCHCHH),
 2.78-2.97 (4H, m, CHH indole, PhCH_2 , $(\text{CH}_3)_2\text{CH}$), 3.01-3.20 (1H, Br m,
 $(\text{CH}_3)_2\text{CH}$), 3.47 (1H, d, 14.40 Hz, CHH indole), 4.77 (1H, br s, NHCNH),


-24-

5.36 (1H, q, 7.57 Hz, CNHCH), 5.58 (1H, s, NHCHN), 6.30 (1H, br s, amide nH), 6.60 (1H, br d, 6.59 Hz, ArH), 6.65 (1H, br d, 8.06 Hz, ArH), 6.94-7.06 (3H, m, 3 ArH), 7.11-7.20 (4H, m, 4 ArH), 7.26-7.34 (2H, m, 2 ArH), 7.38 (1H, d, 7.32 Hz, ArH), 7.82 (1H, br s, indole NH);

IR (film): 3354.0, 1668.0, 1506.0, and 1060.0 cm^{-1} ;

MS m/e (APCI) 537.7 ($\text{M} + \text{H}^+$); Analysis $\text{C}_{34}\text{H}_{40}\text{N}_4\text{O}_2$, C, H, N; $\alpha^D = -30.29^\circ$ (MeOH, c = 0.175 g, 100 mL^{-1} ; mp 228-230°C; HPLC R.T. = 16.96, C^{18} reverse phase, 40% to 100% MeCN:TFA/ H_2O :TFA.

EXAMPLE 4



N-(2-Cyclohexyl-ethyl)-2-[3-(2,6-diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-propionamide

Example 4 was prepared as for Scheme 1 using cyclohexyl ethyl amine.


Example 4 was isolated in 54% yield.

^1H NMR (DMSO-d_6): δ 0.50-1.73 (28H, br, αCH_3 + cyclohexyl + $2 \times (\text{CH}_3)_2\text{CH}$ + CH_2 cyclohexyl), 2.92-3.30 (5H, br, CH_2N + $2 \times (\text{CH}_3)_2\text{CH}$ + CHH indole),

-25-

3.50 (1H, br d, CHH indole), 6.42 (1H, br s, PhNHCNH), 6.83-7.38 7H, br m,
 5 3 ArH + 4 indole H), 7.52 (1H, d, 8.0 z, indole H), 7.71 2H, br, PhNHC + amide
 NH), 10.90 (1H, br, indole NH);
 IR (film): 3289.0, 2924.0, 1668.0, 1652.0, 1520.0, 1456.0, and 740.0 cm⁻¹; MS
 m/e (CI) 531.8 (M⁺ + H); Analysis C₃₃H₄₆N₄O₂•0.2 H₂O, C, H, N;
 10 mp 113-116°C.

EXAMPLE 5



2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-phenyl-propionamide

15 Example 5 was prepared as for Scheme 1 using phenylamine.
 Example 5 was isolated in 69% yield.

¹H NMR (DMSO-d₆): δ 1.11 (12H, br, 2 × (CH₃)₂CH), 1.47 (3H, br s, αCH₃),
 3.29 (2H, br, 2 × (CH₃)₂CH), 3.45 (2H, br, CH₂ indole), 6.43 (1H, br s,

20 PhNHCNH), 6.90-7.39 (10H, br m, 6ArH + 4 indole H), 7.50-.71 (4H, br,

-26-


$$\text{O}$$

$$\parallel$$

$$\text{2ArH} + \text{indole H} + \text{PhNH}\text{C}\text{NH}, 9.70 (1\text{H, br s, amide NH}), 10.98 (1\text{H, br, indole NH});$$

5 IR (film): 3278.0, 2927.0, 1673.0, 1599.0, 1519.0, 1499.0; MS m/e (CI) 497.6 ($\text{M}^+ + \text{H}$); Analysis $\text{C}_{31}\text{H}_{36}\text{N}_4\text{O}_2 \cdot 0.5 \text{H}_2\text{O}$, C, H, N; mp 121-124°C.

EXAMPLE 6



10 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-(2-phenyl-cyclohexyl)-propionamide

Example 6 was prepared as for Scheme 1 using Intermediate III.

Yield (78 mg, 53%).


^1H NMR (CDCl_3): 0.85-2.04 (20H, m, $4 \times \text{CU}_2$), 1.36 (3H, s, $\alpha\text{-CU}_3$), 2.79 (1H, d, CHH), 2.92-3.10 (3H, m, CHH , $2 \times \text{CU}(\text{CU}_3)_2$), 4.46-4.51 (2H, m, NHCH , PhCU), 5.63 (1H, s, CONH), 6.14 (1H, s, NHCO), 6.91-7.28 (13H, m, aromatic), 7.70 (1H, s, NH), 7.92 (1H, bs, CONH);

15 IR (film): 3286, 3061, 2928, 2867, 1674, 1662, 1496, 906, and 734; MS m/e M^+ 580, 405, 377; HPLC 97.6%, R.T. = 16.55, 60% to 100% acetonitrile in water

(___ TFA); $[\alpha]_{\text{D}}^{22} + 67.5^\circ$ ($c = 0.57$, acetone).

-27-

SCHEME 2



Reagents and Conditions:


- i) 2,6-Diisopropyl phenyl isocyanate, triethylamine, DMF, 100°C
 5 ii) HBTU, DIPEA, DMF, 20°C, N-methyl cyclohexyl methyl amine

Synthesis of Example 7Step 1

- To a stirred solution of tryptophan (203 mg, 1.0 mmol) and triethylamine (9 mL, 65 mol) in dioxan (50 mL) was added diisopropyl phenyl isocyanate (203 mg, 1.0 mmol), and the mixture was refluxed for 3 hours. The reaction mixture was allowed to cool to room temperature and was taken up in EtOAc and washed with 1N HCl (aq), brine, and dried (MgSO₄). The solvents were removed *in vacuo* and the residue was triturated with ether to yield IV as a white solid (191 mg, 47%).
 10
 15 IR (film): 2962.0, 1614.0, and 1456.0 cm⁻¹; MS m/e (CI) 408 (M + H).

-28-

EXAMPLE 7



N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-N-methyl-propionamide

5 Example 7 was isolated in 75% yield.

To a stirred solution of the acid IV (122 mg, 0.3 mmol), HBTU (114 mg, 0.3 mmol), and diisopropyl ethyl amine (116 mg, 0.9 mmol) in DMF (50 mL) which had been stirred for 5 minutes was added N-methyl cyclohexyl methyl amine (76.2 mg, 0.6 mmol). The mixture was stirred for 2 hours and then taken up
 10 in EtOAc (150 mL) and washed with NaHCO₃ (aq), 1N HCl (aq), brine, dried (MgSO₄), and concentrated *in vacuo*. The residue was purified on normal phase silica eluting with a gradient of heptane to 6:4 heptane:EtOAc to yield 7 (116.3 mg, 75%).

¹H NMR (CDCl₃): δ 0.51-1.07 (6H, m, cyclohexyl), 1.14 and 1.16 (12H, 2 × d, 15 6.83 Hz, [(CH₃)₂CH] × 2), 1.23-1.60 (5H, m, cyclohexyl), 2.53-2.89 (2H, m,

[(CH₃)₂CH] × 2), 2.57 and 2.67 (3H, 2 × s, CN-CH₃), 3.01-3.26 (4H, m,

20 CHH indole and N(Me)CH₂), 5.16-5.20 (1H, m, NHCNHCH), 5.22-5.27 (1H, m,

αH), 5.72 (1H, m, NHCNH), 6.98-7.02 (1H, m, ArH), 7.08-7.19 (4H, m, 4ArH),

-29-

7.26-7.34 (2H, m, 2ArH), 7.69 (1H, d, 8.06 Hz, ArH), 7.95 (1H, br s, indole NH);


IR (film): 3291.0, 2925.0, 1615.0, 1538.0, 1213.0, and 740.0 cm⁻¹; MS m/e (CI)

518 (M + H); Analysis C₃₂H₄₅N₄O₂, C, H, N; mp 179-181°C; HPLC

R.T. = 18.09, C¹⁸ reverse phase, 10% to 80% MeCN:TFA/H₂O:TFA.

-30-

SCHEME 3









Reagents and Conditions:

- i) p-nitrophenyl isocyanate, pyridine, DMF, 60°C
- 5 ii) HBTU, R, DIPEA, DMF, 20°C
- iii) 2N HCl, MeOH, Reflux



-31-

Table for Scheme 3

Example No.	R
8	
9	
26	 XXI
27	 XXII
28	 XXIII
29	 XXIV (R, S)

-32-

Table for Scheme 3 (cont)

Example No.	R
30	 <p>XXV</p>
31	

Synthesis of Examples 8 and 9, 26 through 30

Step 1

To a mixture of (S)- α Me tryptophan (2.51 g, 11.5 mmol) in DMF (100 mL) was added p-nitro phenyl isocyanate (1.89 g, 11.5 mmol) followed by pyridine (1 mL), and the reaction mixture was heated to 60°C for 30 minutes. The solvent was removed *in vacuo*, and the residue was taken up in 1N NaHCO₃ (aq) and extracted with ether. The aqueous layer was acidified with 5N HCl (aq) to pH 1 and re-extracted with EtOAc, dried (MgSO₄), and concentrated *in vacuo* to give V as a yellow solid (4.07 g, 96.1%).


¹H NMR (DMSO): δ 1.55 (3H, s, α-CH₃), 3.31 (1H, d, obscured by water peak,

CHH indole), 3.48 (1H, d, 14.40 Hz, CHH indole), 6.57 (1H, s, NHCN^OH), 6.82 (1H, t, 7.81 Hz, indole H5), 6.99 (1H, t, 7.32 Hz, indole H6), 7.04 (1H, d, 2.2 Hz, indole H2), 7.30 (1H, d, 8.3 Hz, indole H7), 7.49 (1H, d, 8.06 Hz, indole H4), 7.62 (2H, d, 9.04 Hz, 2 × p-NO₂Ph ArH), 8.16 (2H, d, 9.03 Hz,

-33-

$$\begin{array}{c} \text{O} \\ \parallel \\ 2 \times \text{P-NO}_2 \text{ ArH} \end{array}$$
 9.45 (1H, s, NHCNH), 10.89 (1H, s, indole NH).

EXAMPLE 8



N-Cyclohexylmethyl-3-(1H-indol-3-yl)-2-methyl-2-[3-(4-nitro-phenyl)-ureido]-propionamide

Example 8 was isolated in 54.4% yield.

To a solution of the acid V (150 mg, 0.4 mmol), HBTU (155 mg, 0.4 mmol), and diisopropyl ethyl amine (158 mg, 1.2 mmol) in DMF (100 mL) which had been stirred for 5 minutes was added cyclohexyl methyl amine (250 mg, 2.17 mmol), and the reaction mixture was stirred for 2 hours. The mixture was taken up in EtOAc and washed with 1N HCl (aq), 1N NaHCO₃ (aq), brine, dried (MgSO₄), and concentrated *in vacuo*. The residue was purified on silica eluting with 1:1 heptane:EtOAc to EtOAc to give a yellow solid which was washed with EtOAc to yield pure 8 (104 mg, 54.4%).

¹H NMR (DMSO): δ 0.78-0.86 (2H, m, cyclohexyl), 1.06-1.20 (3H, m, cyclohexyl), 1.40-1.49 (1H, m, cyclohexyl), 1.57 (3H, s, αCH_3), 1.56-1.63 (5H,

m, cyclohexyl), 2.82-2.89 (1H, m, CNHCHH), 2.95-3.01 (1H, m, CNHCHH), 3.34 (1H, d, 14.89 Hz, CHH indole), 3.58 (1H, d, 14.65 Hz, CHH indole),

-34-

6.66 (1H, s, PhNHCNH), 6.81 (1H, t, 7.57 Hz, indole H5), 6.94 (1H, s, indole H2),
 6.98 (1H, t, 7.33 Hz, indole H6), 7.27 (1H, d, 8.06 Hz, indole H7), 7.48 (1H, d,
 8.06 Hz, indole H4), 7.62 (2H, d, 9.3 Hz, 2-p-NO₂Ph ArH), 7.99 (1H,

t, 5.62 Hz, CNH), 8.15 (2H, d, 9.03 Hz, 2 × pNO₂Ph ArH), 9.60 (1H, s,


NHCNH), 10.81 (1H, s, indole NH);

IR (film): 3345.0, 2924.0, 2852.0, 1695.0, 1644.0, 1557.0, 1505.0, 1456.0, 1329.0,
 1302.0, 1231.0, 1112.0, and 741.0 cm⁻¹; MS m/e (APCI) 478.6 (M + H⁺);

Analysis C₂₆H₃₁N₅O₄•0.35 H₂O, C, H, N; mp 129-131 then 208-225°C; HPLC

R.T. = 13.52, C¹⁸ reverse phase, 40% to 100% MeCN:TFA/H₂O:TFA.

EXAMPLE 9



N-(1-Hydroxy-cyclohexylmethyl)-3-(1H-indol-3-yl)-2-methyl-2-[3-(4-nitro-phenyl)-ureido]-propionamide

Example 9 was prepared as for Scheme 3 using 1-amino methyl-1-cyclohexanol.

Example 9 was isolated in 59% yield.

¹H NMR (DMSO): δ 1.13-1.57 (8H, m, cyclohexyl), 1.42 (3H, s, αCH₃),

-35-

2.07-2.12 (2H, m, cyclohexyl), 2.98 (1H, dd, 13.19 and 5.13 Hz, CNHCHH),

5

3.27 (1H, dd, 12.94 and 6.84 Hz, CNHCHH), 3.41 and 3.37 (2H, 2 × d, 14.90 Hz, CHH indole), 6.54 (1H, s, NHCNH), 6.81 (1H, t, 7.57 Hz, indole H5), 6.93 (1H,

10

s, indole H2), 6.98 (1H, t, 7.57 Hz, indole H6), 7.10 (1H, t, 7.33 Hz, ArH),

15

7.15-7.21 (3H, m, 2 ArH + NHCNH), 7.27-7.30 (3H, m, 3 ArH), 7.44 (1H, d, 8.06 Hz, indole H7), 7.66 (2H, d, 9.28 Hz, 2 × $\text{pNO}_2\text{Ph ArH}$), 8.18 (2H, d,

9.28 Hz, 2 $\text{pNO}_2\text{Ph ArH}$), 9.52 (1H, s, CNH), 10.81 (1H, s, indole NH).

IR (film): 3323.0, 1698.3, 1645.0, 1615.2, 1558.5, and 1505.0 cm^{-1} ; MS m/e


(APCI) 554.5 ($\text{M} + \text{H}^+$); Analysis $\text{C}_{26}\text{H}_{31}\text{N}_5\text{O}_5$, C, H, N; mp 182-184°C; HPLC

20

R.T. = 10.53, C^{18} reverse phase, 40% to 100% $\text{MeCN:TFA/H}_2\text{O:TFA}$.

-36-

SCHEME 4



Reagents and Conditions:

- 5 i) 2,6-Diisopropylphenylisocyanate, triethylamine, DMF, 50°C
 ii) HBTU, cyclohexylmethylamine, DIPEA, DMF

Synthesis of Example 10Step 1

10 To a suspension of N-methyl (RS) tryptophan (500 mg, 2.3 mmol) in DMF (30 mL) was added 2,6-diisopropyl phenyl isocyanate (0.54 mL, 2.53 mmol), and triethyl amine (697 mg, 6.9 mmol), and the reaction mixture was heated to 50°C and stirred for 30 minutes. The mixture was allowed to cool to room temperature

-37-

before being taken up in EtOAc and washed with 1N HCl, brine, dried (MgSO₄), and concentrated *in vacuo* to give VI (966 mg, 100%).


¹H NMR (CDCl₃): δ 1.15 (6H, d, 6.84 Hz, (CH₃)₂CH), 1.25 (6H, d, 6.84 Hz, (CH₃)₂CH), 2.94 (3H, s, N-me), 2.88-3.05 (2H, 2 × m, [(CH₃)₂CH]₂),

3.45-3.47 (2H, m, CHH indole), 4.97 (1H, t, 8.06 Hz, αH), 5.81 (1H, s, NHC), 7.10-7.20 (5H, m, 5ArH), 7.22 (1H, t, 7.1 Hz, ArH), 7.26-7.30 (1H, m, ArH), 7.38 (1H, d, 8.06 Hz, ArH), 7.66 (1H, d, J = 7.82 Hz, ArH), 8.17 (1H, s, indole NH);

IR (film): 3320.8, 2963.0, 2291.5, 1716.0, 1652.0, 1507.0, 1466.8, and 743.0 cm⁻¹;

MS m/e (ES) 420.7 (M - H⁺) 421.7 (M⁺).

EXAMPLE 10



N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)-1-methyl-ureido]-3-(1H-indol-3-yl)-propionamide

Example 10 was isolated in 32.6% yield.

To a solution of the acid VI (211 mg, 0.5 mmol) in DMF (50 mL) was added HBTU (189.6 mg, 0.5 mmol), diisopropyl ethyl amine (194 mg, 1.5 mmol), and the mixture was stirred for 10 minutes. Cyclohexyl methyl amine (80 mg, 0.7 mmol) was then added to the reaction mixture and this was stirred for a further 5 hours. The mixture was taken up in EtOAc and washed with 1N HCl (aq),

-38-

NaHCO₃ (aq), brine, dried (MgSO₄), and concentrated *in vacuo*. The residue was purified on normal phase silica eluting with a gradient of heptane to 6:4 heptane:EtOAc to give a solid which was washed with ether to yield pure 10 (84.2 mg, 32.6%).

5 ¹H NMR (CDCl₃): δ 0.82-0.91 (2H, m, cyclohexyl), 1.10-1.20 (8H, m, cyclohexyl), 1.14 (12H, d, 6.84 Hz, [(CH₃)₂CH] × 2), 1.38-1.43 (1H, m,

$\begin{array}{c} \text{O} \\ \parallel \\ \text{CNHCH}_2\text{CH} \end{array}$, 1.58-1.70 (2H, m, [(CH₃)₂CH] × 2), 3.03 (3H, s, N-CH₃),

10 $\begin{array}{c} \text{O} \\ \parallel \\ \text{CNHCH}_2 \end{array}$, 3.08 (2H, t, 6.35 Hz, CNHCH₂), 3.30 (1H, dd, 9.77 and 15.87 Hz, CHH indole), 3.36 (1H, dd, 6.10 and 15.87 Hz, CHH indole), 5.29-5.33 (1H, m, αH), 5.65 (1H, s, PhNH₂C), 6.50 (1H, bt, amide NH), 7.08 (1H, d, 2.2 Hz, indole H2),

15 $\begin{array}{c} \parallel \\ \text{O} \end{array}$
7.10-7.20 (3H, m, 3ArH), 7.20 (1H, t, 7.10 Hz, ArH), 7.22-7.26 (1H, m, ArH), 7.37 (1H, d, 8.3 Hz, ArH), 7.67 (1H, d, 7.57 Hz, 1ArH), 7.97 (1H, s, indole NH);


IR (film): 3323.0, 2925.0, 1668.2, 1645.0, and 1506.0 cm⁻¹; MS m/e (APCI)

20 515.9 (M⁺), 517.7 (M + H⁺); Analysis C₃₂H₄₄N₄O₂, C, H, N; mp 183-185.5°C;

HPLC R.T. = 18.41, C¹⁸ reverse phase, 40% to 100% MeCN:TFA/H₂O:TFA.

-39-

SCHEME 5















Reagents and Conditions:

- i)** Boc_2O , NaHCO_3 , dioxan
- ii)** LiOH , THF, MeOH
- iii)** HBTU, R, DIPEA, DMF or DCC, PFP, R, EtOAc
- iv)** TFA, DCM
- v)** $\text{R}'\text{NCO}$, THF

5

-40-

Table for Scheme 5

Example No.	R	R'
11		
12		
13		
14		
15		
32		

-41-

Table for Scheme 5 (cont)

Example No.	R	R'
16		
17 (R,S-stereo-chemistry)		

Synthesis of Examples 12-16Step 1 as for Examples 11 and 17.Step 2

- 5 To a solution of the acid VII (2.067 g, 6.5 mmol), HBTU (2.47 g, 6.5 mmol), and diisopropyl ethyl amine (2.52 g, 19.5 mmol) in DMF (130 mL) which had been stirred ~5 minutes was added the amine II (1.24 g, 6.5 mmol), and stirring was continued for a further 2 hours. The reaction mixture was taken up in EtOAc and washed with NaHCO₃ (aq), 1N HCl (aq), dried (MgSO₄), and
- 10 concentrated *in vacuo*. The residue was purified on reverse phase silica eluting with 77% MeOH/H₂O to obtain pure VIII (R = II) (2.17 g, 68%).

¹H NMR (CDCl₃): δ 1.27-1.63 (8H, m, cyclohexyl), 1.40 (9H, s, (CH₃)₃C), 1.52 (3H, s, αCH₃), 2.0-2.13 (2H, m, cyclohexyl), 3.31 (1H, d, 14.65 Hz,

- 15 CHH indole), 3.29-3.50 (3H, m, CHH indole and CNHCH₂), 5.05-5.15 (1H, br s, CHH indole), 5.29-5.40 (3H, m, CHH indole and CNHCH₂), 5.05-5.15 (1H, br s, CNH), 6.93 (1H, s, indole H₂), 7.0-7.12 (2H, m, 2ArH), 7.16 (1H, t, 8.06 Hz,

-42-

O
||

ArH), 7.10-7.22 (1H, m, NH $\underline{\text{C}}$), 7.31 (2H, t, 7.81 Hz, 2ArH), 7.52 (1H, d, 7.57 Hz, ArH), 7.63 (1H, t, 7.81 Hz, ArH), 7.99 (1H, br s, indole NH), 8.50 (1H, d, 3.66 Hz, pyridyl H);

IR (film): 3333.0, 2928.0, 1652.0, 1471.0, and 1163.0 cm⁻¹; MS m/e (APCI) 491.6 (M + H⁺); Analysis C₂₉H₃₈N₄O₃, C, H, N; mp: 78.5-79.5°C; HPLC R.T. = 8.47 and 8.73, C¹⁸ reverse phase, 40% to 100% MeCN:TFA/H₂O:TFA.


Step 3

VIII (R = II) (473 mg, 0.96 mmol) was dissolved in formic acid (30 mL) and stirred for 5 hours. The mixture was basified with dilute sodium hydroxide solution to pH 14 and extracted with EtOAc, dried (MgSO₄), and concentrated *in vacuo* to give IX (R = II) (300 mg, 80%).

¹H NMR (CDCl₃): δ 1.27-1.63 (8H, m, cyclohexyl), 1.32 (3H, s, αCH₃), 2.0-2.2 (2H, 2 × m, cyclohexyl), 2.79 (1H, d, 14.65 Hz, indole CHH), 3.35 (1H, d, 14.65 Hz, indole CHH), 3.36 (1H, dd, 6.35 Hz, 13.18 Hz, CNHCHH), 3.42 (1H, dd, 6.10 and 13.18 Hz, CHHNHC), 7.00 (1H, d, 2.44 Hz, indole H₂), 7.03-7.19 (4H, m, 4ArH), 7.35 (1H, d, 8.06 Hz, ArH), 7.52 (1H, td, 1.95 and 7.57 Hz, ArH), 7.59 (1H, d, 7.82 Hz, ArH), 7.60-7.68 (1H, br t, CNH), 8.02 (1H, br s, indole NH), 8.51-8.58 (1H, m, pyridyl H); MS m/e (ES) 391.7 (M + H⁺).

-43-

EXAMPLE 12



3-(1H-Indol-3-yl)-2-methyl-2-{3-[1-(4-nitro-phenyl)-ethyl]-ureido}-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide

5 Example 12 was isolated in 39% yield.

To a solution of the amine IX (R = II) (100 mg, 0.26 mmol) in THF (100 mL) was added 4-nitro- α -methyl benzyl isocyanate (180 mg, 0.94 mmol), and the solution was stirred for 4 hours at room temperature. The reaction mixture was taken up in EtOAc and washed (H₂O), dried (MgSO₄), and concentrated
 10 *in vacuo*. The residue was taken up in EtOAc and crystallized to yield 12 (58.6 mg, 39%).


¹H NMR (DMSO): δ 1.08-1.48 (8H, m, cyclohexyl), 1.24 (3H, s, α -CH₃), 1.33 (3H, d, 7.08 Hz, PNO₂PhCHCH₃), 2.03-2.18 (2H, m, cyclohexyl), 3.07 (1H,

15 dd, 5.62 and 12.94 Hz, CNHCHH), 3.21-3.15 (2H, m, CHH indole and
 CNHCHH), 3.34-3.29 (1H, d, obscured by water peak CHH indole), 4.90 (1H, m,
 20 CHCH₃), 5.93 (1H, s, CHNH₂CNH), 6.77 (1H, d, 7.32 Hz, ArH), 6.86-6.90 (2H,

-44-

O
 \parallel
 m, 1ArH, and CNH), 7.01 (1H, t, 7.32 Hz, ArH), 7.13-7.16 (1H, m, ArH),
 5 7.27-7.30 (2H, m, 2ArH), 7.36-7.40 (2H, m, CNH and ArH), 7.55 (2H, d, 8.79 Hz,
 2 × p-NO₂Ph ArH), 7.64 (1H, td, 1.95 and 7.81 Hz, ArH), 8.16 (2H, d, 8.54 Hz,
 2 × p-NO₂Ph ArH), 8.50 (1H, d, 2.93 Hz, pyridyl H), 10.85 (1H, s, indole NH);
 IR (film): 3340.0, 2923.6, 1642.0, 1520.0, 1345.6, and 1107.0 cm⁻¹; MS m/e
 10 (APCI) 583.6 (M + H⁺); Analysis C₃₃H₃₈N₆O₄, C, H, N; mp 202-203.5°C;
 HPLC R.T. = 9.38 and 9.77, C₁₈ reverse phase, 40% to 100%
 MeCN:TFA/H₂O:TFA;

EXAMPLE 13



15 2-[3-(4-Cyano-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide

Example 13 was prepared as for Scheme 5 using Intermediate II and 4-cyano phenyl isocyanate.

Example 13 was isolated in 37% yield.

20 ¹H NMR (DMSO): δ 1.13-1.55 (8H, m, cyclohexyl), 1.41 (3H, s, αCH₃),

O
 \parallel
 2.16-2.23 (2H, m, cyclohexyl), 3.09 (1H, dd, 5.37 and 12.94 Hz, CNHCHH),

-45-


3.28-3.39 (3H, m obscured by water peak, CNHCHH and indole CHH), 6.44 (1H,

5 s, NHCNH), 6.81 (1H, t, 7.32 Hz, indole H5), 6.92 (1H, d, 2.20 Hz, indole H2), 6.98 (1H, t, 7.08 Hz, indole H6), 7.07-7.10 (1H, m, ArH), 7.28 (2H, t, 8.06 Hz,

10 2ArH), 7.41 (1H, d, 8.06 Hz, indole H7), 7.44-7.52 (3H, m, 2ArH and CNH), 7.56 (2H, d, 8.79 Hz, 2 × pNO₂Ph ArH), 7.68 (2H, d, 8.79 Hz, 2 × pNO₂Ph ArH),

8.47-8.49 (1H, m, pyridyl H), 9.22 1H, s, CNH), 10.81 (1H, s, indole NH);
 15 IR (film): 3352.0, 2934.2, 1652.0, 1532.0, and 1113.0 cm⁻¹; MS m/e (APCI): 535.5 (M + H⁺); Analysis C₃₂H₃₄N₆O₂, C, H, N; mp 234.5-237°C; HPLC R.T. = 6.75 and 7.02, C¹⁸ reverse phase, 40% to 100% MeCN:TFA/H₂O:TFA;

EXAMPLE 14



20 3-(1H-Indol-3-yl)-2-methyl-2-[3-(4-nitro-phenyl)-ureido]-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide

Example 14 was isolated in 63.3% yield.

Example 14 was prepared as for Scheme 5 using Intermediate II and 4-nitrophenyl isocyanate.

-46-

^1H NMR (DMSO): δ 1.11-1.55 (8H, m, cyclohexyl), 1.44 (3H, s, αCH_3),


2.18-2.25 (2H, m, cyclohexyl), 3.09 (1H, dd, 5.37 and 13.18 Hz, CNHCHH),

3.29-3.38 (3H, m, CHH indole and CNHCHH), 6.54 (1H, s, NHCNH), 6.81 (1H, t, 8.06 Hz, indole H5), 6.93 (1H, s, indole H2), 6.98 (1H, t, 7.08 Hz, indole H6), 7.07-7.10 (1H, m, ArH), 7.28 (2H, t, 9.03 Hz, 2 ArH), 7.42 (1H, d, 7.81 Hz, indole H7), 7.49-7.60 (2H, m, amide NH and 1 ArH), 7.62 (2H, d, 9.28 Hz, 2 \times p- NO_2Ph ArH), 8.16 (2H, d, 9.28 Hz, 2 \times p- NO_2Ph ArH), 8.48-8.50 (1H, m, pyridyl H),

9.49 1H, s, Ph NHCNH), 10.81 (1H, s, indole NH);

IR (film): 3363.0, 2934.2, 1644.2, 1454.1, 1433.0, and 1046.0 cm^{-1} ; MS m/e (APCI): 555.5 ($\text{M} + \text{H}^+$); Analysis $\text{C}_{31}\text{H}_{34}\text{N}_6\text{O}_4$, C, H, N; mp 215-219°C; HPLC R.T. = 8.79, C^{18} reverse phase, 40% to 100% MeCN:TFA/ H_2O :TFA.

EXAMPLE 15



3-(1H-Indol-3-yl)-2-methyl-N-(1-pyridin-2-yl-cyclohexylmethyl)-
2-[3-(4-trifluoromethyl-phenyl)-ureido]-propionamide

Example 15 was isolated in 20% yield.

-47-

Example 15 was prepared as for Scheme 5 using Intermediate II and 4-trifluoromethylphenylisocyanate.

^1H NMR (DMSO): δ 1.12-1.55 (8H, m, cyclohexyl), 1.40 (3H, s, αCH_3), 2.18-2.26 (2H, m, cyclohexyl), 3.08 (1H, dd, 5.37 and 12.94 Hz, $\text{CNHC}\underline{\text{H}}\text{H}$),

5



3.27-3.36 (3H, obscured by water peak, $\text{C}\underline{\text{H}}\text{H}$ indole and $\text{CNHC}\underline{\text{H}}\text{H}$), 6.38 (1H, s,

10



$\text{NHCN}\underline{\text{H}}$), 6.81 (1H, t, 7.81 Hz, indole H5), 6.93 (1H, d, 2.2 Hz, indole H2), 6.98 (1H, t, 7.57 Hz, indole H6), 7.07-7.10 (1H, m, $\text{Ar}\underline{\text{H}}$), 7.29 (2H, t, 9.03 Hz,

15

2 $\text{Ar}\underline{\text{H}}$), 7.42 (1H, d, 8.06 Hz, indole H7), 7.46-7.51 (2H, m, $\text{Ar}\underline{\text{H}}$ and $\text{NHC}\underline{\text{H}}$),



7.59 (4H, s, 4 \times $\text{Ar}\underline{\text{H}}$), 8.48 8.49 (1H, m, pyridyl $\underline{\text{H}}$), 9.13 (1H, s, $\text{NHC}\underline{\text{H}}$), 10.83 (1H, br s, indole $\text{NH}\underline{\text{H}}$);

20




IR (film): 3360.0, 2934.2, 1651.9, 1559.3, 1440.3, 1334.6, and 1070.0 cm^{-1} ; MS

m/e (APCI): 578.5 ($\text{M} + \text{H}^+$); Analysis $\text{C}_{32}\text{H}_{34}\text{N}_5\text{O}_2\text{F}_3$, C, H, N; HPLC

R.T. = 10.99, C^{18} reverse phase, 40% to 100% MeCN:TFA/ H_2O :TFA.

-48-

EXAMPLE 16



4-(3-{2-1H-Indol-3-yl}-1-methyl-1-[(1-pyridin-2-yl-cyclohexylmethyl)-
carbamoyl]-ethyl}-ureido)-benzoic acid ethyl ester

5 Example 16 was prepared as for Scheme 5 using Intermediate II and ethyl-4-isocyanatobenzoate.

Example 16 was isolated in 55% yield.

¹H NMR (CDCl₃): δ 1.26-1.61 (8H, m, cyclohexyl), 1.39 (3H, t, 7.08 Hz, CH₃CH₂O), 1.70 (3H, s, αCH₃), 2.03-2.1 (2H, m, cyclohexyl), 3.18 (1H, dd,

10 4.15 and 13.18 Hz, CNHCHH), 3.30 (1H, d, 14.65 Hz, CHH indole), 3.51 (1H, dd,

15 5.86 and 12.94 Hz, CNHCHH), 3.53 (1H, d, 14.65 Hz, indole CHH), 4.35 (1H,

q^t, 7.08 Hz, CH₃CH₂O), 5.83 (1H, s, NHCNH), 6.85 (1H, d, 2.44 Hz, ArH),

20 6.98 (1H, t, 7.81 Hz, ArH), 7.02-7.07 (2H, m, ArH and NHC), 7.11 (1H, t,

7.08 Hz, ArH), 7.24-7.33 (4H, m, 4ArH), 7.41-7.45 (2H, m, ArH and NHC),

25 7.59 (1H, td, 7.57 and 1.95 Hz, ArH), 7.90 (2H, d, 8.79 Hz, 2ArH), 7.95 (1H, br s, indole NH), 8.44-8.45 (1H, m, pyridyl H);

IR (film): 3342.0, 2931.0, 1645.0, 1538.0, 1279.0, 1174.0, and 1107.0 cm^{-1} ; MS m/e (APCI) 582.5 ($M + H^+$); Analysis $\text{C}_{34}\text{H}_{39}\text{N}_5\text{O}_4$, C, H, N; mp 117-120°C; HPLC R.T. = 9.58, C^{18} reverse phase, 40% to 100% MeCN:TFA/ H_2O :TFA.

Synthesis of Examples 11 and 17

5 Step 1

To a stirring solution of (S)- α -methyl tryptophan methyl ester (5.0 g, 22 mmol) in dioxan (50 mL) water (50 mL) was added NaHCO_3 (3.0 g, 36 mmol) followed by di-*t*-butyl dicarbonate (5.0 g, 23 mmol). Stirring was continued for 18 hours at ambient temperature. The mixture was acidified (HCl, 200 mL, 2N aq, cautiously at first) and the products extracted (EtOAc, 300 mL). The organic phase was dried (MgSO_4) and evaporated to dryness *in vacuo* (60°C). The residual brown oil was purified by flash column chromatography (silica gel, eluant 40% EtOAc/60% heptane). Recovered 7.0 g (99%) of the protected ester as a pale yellow oil, which was not fully characterized. To a stirring solution of this ester (7.0 g, 21 mmol) in MeOH (60 mL)/THF (60 mL) was added a solution of $\text{LiOH}\cdot\text{H}_2\text{O}$ (1.5 g, 35 mmol) in water (20 mL). Stirring was continued for 18 hours at ambient temperature. The mixture was acidified (HCl, 200 mL, 2N aq) and the products extracted (EtOAc, 2 \times 150 mL). The combined organics were dried (MgSO_4) and evaporated to dryness *in vacuo* (60°C). Recovered (VII) 6.8 g (99%) as a pale yellow oil. This was not fully characterized.

IR (film): 1702 and 1694 cm^{-1} .

Step 2

To a stirring solution of (VII) (0.5 g, 1.6 mmol) in EtOAc (30 mL) was added N,N-dicyclohexyl carbodiimide (0.5 g, 2.4 mmol) and pentafluorophenol (0.4 g, 2.2 mmol). Stirring was continued for 30 minutes at ambient temperature, then the white precipitate was removed by filtration. To the filtrate was added, with stirring, aminomethyl cyclohexane (0.4 mL, 0.3 g, 3.0 mmol). Stirring was continued for 30 minutes at ambient temperature, then the reaction mixture was

-50-

washed with HCl (50 mL, 2N aq), dried (MgSO₄), and evaporated to dryness
in vacuo (60°C). The residue was purified by flash column chromatography (silica
 gel, eluant 80% EtOAc/heptane) followed by reverse phase column
 chromatography (74% MeOH/26% H₂O). This gave (VIII) (R = CH₂ cyclohexyl)
 5 as a white foam (0.54 g, 83%).

¹H NMR (DMSO-d₆): δ 0.83 (2H, br, cyclohexyl), 1.08-1.72 (21H, m, α-CH₃ +
 (CH₃)₃O + cyclohexyl), 2.78-3.02 (2H, br, CH₂-N), 3.18 (1H, br, CHH indole),

10 3.31 (obscured, CHH indole), 6.40 (1H, br s, OCNH), 6.92 (1H, t, 7.6 Hz,
 indole H), 6.96 (1H, s, indole H), 7.03 (1H, t, 7.6 Hz, indole H), 7.31 (1H, d,
 8.0 Hz, indole H), 7.48 (1H, d, 7.6 Hz, indole H), 7.61 (1H, br, amide NH),
 10.85 (1H, br, indole NH);

IR (film): 3322, 2922, 1698, 1652, 1519, 1490, and 1455 cm⁻¹; MS m/e (CI)
 15 414 (M⁺ + H); , mp 82-85°C; Analysis C₂₄H₃₅N₃O₃·0.1 H₂O, C, H, N; ;


$\alpha \frac{20}{D} = -29^\circ$ (c = 0.5, MeOH).

Step 3

To a solution of (VIII) (0.14 g, 0.34 mmol) in CH₂Cl₂ (30 mL) was added
 trifluoroacetic acid (0.1 mL, 1.3 mmol), and the reaction was warmed to reflux for
 20 30 minutes, then allowed to cool to ambient temperature. The mixture was taken
 up in EtOAc (100 mL) and washed (Na₂CO₃, 2N aq, 100 mL), dried (MgSO₄),
 and evaporated to dryness *in vacuo* (60°C). Recovered (IX) as a yellow oil
 (109 mg, 103%). This was to fully characterized.

-51-

EXAMPLE 11



N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-propionamide

5 Example 11 was isolated in 74% yield.

To a stirring solution of (IX) (109 mg, 0.34 mmol) in THF (40 mL) was added 2,6-diisopropyl phenyl isocyanate (0.15 g, 0.7 mmol), and the reaction was heated to reflux for 30 minutes, then allowed to cool to ambient temperature. Volatiles were removed *in vacuo* (60°C), and the residue was purified by flash
 10 column chromatography (silica gel, eluant 50% EtOAc/50% heptane) followed by reverse phase column chromatography (63% acetonitrile/37% water). Recovered Example 11 as a white solid (132 mg, 74%), mp 229-231°C.

¹H NMR (DMSO-d₆): δ 0.50-1.70 (26H, br m, αCH₃ + 2 × (CH₃)₂CH + cyclohexyl), 2.88 (2H, br, CH₂N), 3.10-3.60 (4H, br, 2 × (CH₃)₂CH +

15 CHH indole), 6.45 (1H, br, PhNHCNH), 6.94 (1H, br, indole CH), 7.00-7.80


20 (9H, br m, 4 × indole CH + PhNHCNH + amide NH + 3 × aromatic CH), 10.90 (1H, br s, indole NH);

IR (film): 3287, 2925, 1668, and 1519 cm⁻¹;

-52-

MS m/e (CI) 517 ($M^+ + H$); Analysis $C_{32}H_{44}N_4O_2$, C, H, N; mp 229-231 °C;

$$\alpha \frac{20}{D} = 2^\circ \text{ (c = 0.25, MeOH).}$$

EXAMPLE 17

5 N-Cyclohexylmethyl-2-[3-(2,6-dimethoxy-phenyl)-ureido]-3-(1H-indol-3-yl)-
2-methyl-propionamide

Example 17 was prepared as for Scheme 5 using cyclohexylmethylamine and 2,6-dimethoxy phenylisocyanate.

Example 17 was isolated as a white amorphous solid (70 mg).

10 1H NMR ($CDCl_3$): δ 0.90 (2H, m), 1.20 (3H, m), 1.30 (2H, m), 1.40 (1H, m),
 1.65 (3H, s), 1.70 (2H, m), 2.90 (1H, m), 3.05 and 3.45 (2H, ABq, $J = 15$ Hz),
 3.20 (1H, m), 3.58 (6H, s), 5.20 (1H, s), 5.70 (1H, s), 6.45 (2H, m), 6.82 (1H, s),
 6.90 (1H, br s), 7.00 (1H, br s), 7.15 (2H, m), 7.30 (1H, d, $J = 6$ Hz), 7.45 (1H, d,
 $J = 6$ Hz), 8.10 (1H, br s);

15 IR ($CDCl_3$, film): 3306, 3050, 2924, 1668, 1652, 1594, and 1258 cm^{-1} ;


Analysis calculated for $C_{28}H_{36}N_4O_4$:

C, 68.27; H, 7.37; N, 11.37.

Found: C, 68.21; H, 7.55; N, 11.01.

-53-

SCHEME 6



Reagents and Conditions:

- i) Boc_2O , 10% Na_2CO_3 , dioxan
- 5 ii) HBTU, 2,6-diisopropylphenylamine, DIPEA, DMF
- iii) TFA, DCM
- iv) α -t-butyl benzyl isocyanate, THF

-54-

Synthesis of Example 18Step 1

To a solution of (S)-tryptophan (5.1 g, 25 mmol) in 10% Na₂CO₃ (aq) (61 mL) and dioxan (150 mL) was added di tertiary butyl dicarbonate (5.67 g, 26 mmol), and the mixture was stirred for 18 hours. The solvent was removed *in vacuo*, and the residue was taken up in water and EtOAc. The mixture was acidified to pH 2-3 and extracted with EtOAc, dried (MgSO₄), and concentrated *in vacuo* to yield X as a white foam (7.6 g, 100%).

¹H NMR (CDCl₃): δ 1.43 (9H, s, C(CH₃)₃), 3.32 (2H, m, CH₂ indole), 4.66 (1H, m, αCH), 5.06 (1H, m, NH), 7.02 (1H, s, ArH), 7.10 (1H, t, ArH), 7.20 (1H, t, ArH), 7.35 (1H, d, 8 Hz, ArH), 7.60 (1H, d, 7.6 Hz, ArH), 8.14 (1H, br s, NH indole).

Step 2

To a mixture of the acid X (3.04 g, 10 mmol), HBTU (3.79 g, 10 mmol), and diisopropyl ethyl amine (3.77 g, 30 mmol) in DMF (100 mL) which had been stirred for 20 minutes was added diisopropyl aniline, and the mixture was stirred for a further 18 hours. The solvent was removed *in vacuo*, and the residue was taken up in EtOAc and washed with ammonium chloride saturated solution, brine, dried (MgSO₄), and concentrated *in vacuo*. The residue was purified on normal phase silica with 2.5% MeOH in DCM to yield XI (1.39 g, 30%).


¹H NMR (CDCl₃): δ 0.98-1.06 (12H, m, [(CH₃)₂CH]₂), 1.46 (9H, s, C(CH₃)₃), 2.7 (2H, m, [CH(CH₃)₂]₂), 3.34 (2H, dd, 3.6 and 8 Hz, CH₂ indole), 4.70 (1H, m, αH), 5.20 (1H, br s, CNH), 7.09-7.27 (7H, m, 6ArH + CNH), 7.39 (1H, d, 8.0 Hz, ArH), 7.75 (1H, d, 8.0 Hz, ArH), 8.10 (1H, s, indole NH); IR (film): 3289.0, 2966.0, 1694.9, 1668.0, 1505.0, 1366.0, 1250.0, 1167.0, 910.0, and 739.0 cm⁻¹; MS m/e (Fab) 464 (M + H⁺); Analysis C₂₈H₃₇N₃O₃, C, H, N; mp 98-100°C.

-55-

Step 3

XI (1.0 g, 2.2 mmol) was dissolved in formic acid (30 mL) and stirred for 5 hours. The mixture was basified with dilute sodium hydroxide solution to pH 14 and extracted with EtOAc, dried (MgSO₄), and concentrated *in vacuo* to give XII (745 mg, 95%) as a crude yield which was used without further purification in the next step.

EXAMPLE 18



N-(2,6-Diisopropyl-phenyl)-2-[3-(2,2-dimethyl-1-phenyl-propyl)-ureido]-3-(1H-indol-3-yl)-propionamide

To a solution of the amine XII (51.0 g, 0.14 mmol) in THF (50 mL) was added α -t-butyl benzyl isocyanate (27 mg, 0.14 mmol), and the mixture was stirred at room temperature for 15 hours. The solvent was removed under reduced pressure and the residue purified by column chromatography using 1:1 EtOAc/heptane as eluant to yield 18 as a white solid (>7 mg, >10%).


¹H NMR (CDCl₃): δ 0.81 and 0.85 (9H, 2 \times s, t-butyl), 0.93 (6H, d, 7.20 Hz, (CH₃)₂CH), 1.02 (6H, d, 6.8 Hz, (CH₃)₂CH), 2.58-2.68 (2H, m, [(CH₃)₂CH]₂), 3.2-3.7 (2H, m, CH₂ indole), 4.40-4.50 (1H, m, α H), 4.8-5.5 (3H, m,

-56-

$\begin{array}{c} \text{O} \\ \parallel \\ \text{CNH} \end{array} \times 2$ and $\begin{array}{c} \text{O} \\ \parallel \\ \text{PhCHC}(\text{CH}_3)_3 \end{array}$, 6.7-6.8 (1H, m, CNH), 7.0-7.26 (11H, m, 11ArH),
7.4 and 7.44 (1H, 2 \times d, ArH), 7.65-7.75 (1H, m, 1ArH), 7.85 and 7.05 (1H,
5 2 \times br s, indole NH); IR (film): 3387.7, 3296.8, 1653.8, 1663.3, and 1552.8 cm^{-1} ;
Analysis $\text{C}_{35}\text{H}_{44}\text{N}_4\text{O}_2$, C, H, N; mp 160-161°C.

-57-





SCHEME 7



Reagents and Conditions:

- i) 2,6-diisopropyl phenyl isocyanate, DMF, 60°C
5 ii) Intermediate II, HBTU, DIPEA, DMF
iii) Pd/C, H₂, EtOH

Table for Scheme 7

Example No.	Ar
19	
20	
21	
22	


Synthesis of Example 19

Step 1

5 To a suspension of the racemic amino acid (500 mg) in THF (10 mL) was added NEt₃ (244 mg) followed by the isocyanate (250 mg). The reaction mixture was refluxed for 4 days, evaporated to dryness, and the residue partitioned between EtOAc and 0.1 M HCl to yield the crude acid XIII (Ar = 2-pyridine-N-oxide) as a yellow gum (405 mg). The compound was taken without purification onto the next step.

-59-

EXAMPLE 19



2-[3-(2,6-Diisopropyl-phenyl)-ureido]-2-methyl-3-(1-oxy-pyridin-2-yl)-
N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide

5 To a solution of the acid XIII (Ar = 2-pyridine-N-oxide) (200 mg), HBTU (198 mg) and Intermediate II (100 mg) in DMF (3 mL) was added DIPEA (135 mg). The reaction mixture was stirred at room temperature for 2 days, evaporated to dryness, and the residue partitioned between EtOAc/H₂O to yield the crude product as a yellow gum. This was then purified by column chromatography
 10 to yield Example 19 as a white amorphous solid (195 mg).

¹H NMR (CDCl₃): δ 0.95 (2H, br s), 1.05 (2H, br s), 1.20-1.60 (8H, m), 1.70 (3H, br s), 2.20 (2H, m), 3.10-3.50 (4H, m), 5.50 (1H, s), 7.00-7.20 (5H, m), 7.40 (3H, m), 7.60 (2H, m), 7.80 (1H, br s), 8.60 (1H, s);

IR (CDCl₃, film): 3253, 3050, 2931, 1667, 1661, 1531, and 1441 cm⁻¹;

15 Analysis for C₃₄H₄₅N₅O₃•0.5 CH₂Cl₂:

Calculated: C, 67.47; H, 7.55; N, 11.40.

Found: C, 67.89; H, 7.58; N, 11.63.


Synthesis of Example 20

Step 1

20 As for Step 1 in synthesis of Example 19, yield of XIII (Ar = 2-trifluoromethyl phenyl) was 280 mg. Used without purification in the next step.

-60-

EXAMPLE 20



2-[3-(2,6-Diisopropyl-phenyl)-ureido]-2-methyl-N-(1-pyridin-2-yl-cyclohexylmethyl)-3-(2-trifluoromethyl-phenyl)-propionamide

5 As for Step 2 in synthesis of Example 19, yield of Example 20 was 100 mg (amorphous solid).

^1H NMR (CDCl_3): δ 0.90 (2H, br s), 1.10 (12H, br s), 1.30-1.60 (8H, m),
1.55 (3H, s), 2.00 (2H, m), 3.10 (1H, br s), 3.30-3.50 (3H, m), 5.10 (1H, s),
5.50 (1H, s), 7.10-7.30 (9H, m), 7.50 (1H, d, $J = 8$ Hz), 7.65 (1H, t, $J = 7$ Hz),
10 8.50 (1H, d, $J = 2$ Hz);

IR (CDCl_3 , film): 3334, 3050, 2932, 1668, 1651, 1538, and 1311 cm^{-1} ;

Analysis for $\text{C}_{36}\text{H}_{45}\text{F}_3\text{N}_4\text{O}_2$:

Calculated: C, 69.43; H, 7.28; N, 8.99.

Found: C, 69.43; H, 7.38; N, 8.70.

15


Synthesis of Example 21

Step 1

As for Step 1 in synthesis of Example 19, yield of XIII (Ar = 2-nitrophenyl) was 450 mg. Used without purification in the next step.

-61-

EXAMPLE 21



2-Methyl-3-(2-nitro-phenyl)-2-[3-(4-nitro-phenyl)-ureido]-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide

5 As for Step 2 in synthesis of Example 19, yield of Example 21 was 80 mg (amorphous white solid).

¹H NMR (CDCl₃): δ 0.90 (2H, br s), 1.10 (12H, br s), 1.30-1.50 (8H, m),
1.60 (3H, s), 2.10 (2H, m), 3.10 (1H, m), 3.30-3.60 (3H, m), 5.50 (2H, br s),
7.10 (4H, m), 7.30 (3H, m), 7.35 (2H, d, J = 8 Hz), 7.65 (2H, m), 8.60 (1H, d,
10 J = 2 Hz);

IR (CDCl₃, film): 3335, 3050, 2931, 1667, 1651, 1527, and 1351 cm⁻¹;


Analysis for C₃₅H₄₅N₅O₄•0.2 heptane:

Calculated: C, 70.53; H, 7.84; N, 11.30.

Found: C, 70.92; H, 7.91; N, 11.06.

-62-

EXAMPLE 22



2-[3-(2,6-Diisopropyl-phenyl)-ureido]-2-methyl-3-pyridin-2-yl-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide

To a solution of the N-oxide 19 (153 mg, 0.27 mmol) in ethanol (50 mL) was added 10% Palladium on Carbon, and the reaction mixture was shaken on a Parr hydrogenation apparatus under 55 psi of hydrogen at 35°C for 20 hours. The reaction mixture was filtered through celite, and the filtrate was concentrated *in vacuo*. The residue was purified on normal phase silica eluting with a gradient of heptane to 1:1 heptane:EtOAc to yield 22 (24.9 mg, 16.7%).

¹H NMR (CDCl₃): δ 0.99-1.05 (6H, m, (CH₃)₂CH), 1.05-1.20 (6H, m, (CH₃)₂CH), 1.31-1.69 (8H, m, cyclohexyl), 1.56 (3H, s, αCH₃), 2.12-2.21 (2H, m, cyclohexyl), 2.72-2.75 (1H, m, (CH₃)CH), 3.10-3.20 (3H, m, pyridyl CH₂,

(CH₃)₂CH), 3.40 (1H, dd, 13.43 and 5.86 Hz, CNHCH), 3.53 (1H, dd, 13.43,

6.35 Hz, CNHCH), 5.46 (1H, s, PhNHCNH), 6.92 (1H, br t, 5.13 Hz,


CNH-amide), 7.08-7.12 3H, m, 3ArH), 7.22-7.26 (2H, br s, PhNHCNH, ArH), 7.27-7.48 (4H, m, 4ArH), 7.62-7.66 (2H, m, 2ArH), 8.60-8.62 (1H, m, ArH);

-63-

IR (film): 3278.0, 2929.0, 1668.0, 1590.0, 1520.0, 1471.0, and 1208.0 cm^{-1} ; MS
m/e (APCI) 556.0 ($\text{M} + \text{H}^+$); Analysis $\text{C}_{34}\text{H}_{45}\text{N}_5\text{O}_2 \cdot 0.25 \text{H}_2\text{O}$, C, H, N;
mp 185-186°C; HPLC R.T. = 6.16, C^{18} reverse phase, 40% to 100%
MeCN:TFA/ H_2O :TFA.

-64-

SCHEME 8



Reagents and Conditions:

- i) 2,6-Diisopropyl phenyl isocyanate, DMF, 60°C
- 5 ii) Intermediate II, HBTU, DIPEA, DMF
- iii) Formic acid, DCM

Synthesis of Example 23Step 1

To a mixture of N-trityl histidine (0.99 g, 2.5 mmol) in THF (70 mL) and DMF (20 mL) was added pyridine (396 mg, 5 mmol) followed by diisopropyl phenyl isocyanate (1.02 g, 5 mmol), and the mixture was refluxed for 1.5 hours. The reaction mixture was allowed to cool to room temperature before being taken up in EtOAc and washed with 1N HCl (aq), dried (MgSO₄), and concentrated *in vacuo*. The residue was used crude for the next step (2.20 g, 100%) XIV.

Step 2


To a solution of the acid XIV (500 mg, 0.81 mmol) in DMF (50 mL) was added HBTU (309 mg, 0.81 mmol) and diisopropyl ethyl amine (316 mg, 2.43 mmol), and the mixture was stirred for 5 minutes. The amine II (155 mg, 0.81 mmol) was then added to the reaction mixture which was then stirred for a further 2 hours. The mixture was taken up in EtOAc and washed with NaHCO₃ (aq), brine, dried (MgSO₄), and concentrated *in vacuo*. The residue was purified on normal phase silica eluting with a gradient of heptane:EtOAc 1:1 to EtOAc and then repurified on reverse phase silica eluting with MeOH to yield pure XV (120 mg, 7.8%).

¹H NMR (CDCl₃): δ 0.90-1.64 (20H, 4 × m, [(CH₃)₂CH]₂ and cyclohexyl -8H), 2.05-2.18 (2H, m, cyclohexyl), 2.60-2.70 (1H, m, (CH₃)₂CH), 2.96 (1H, dd, 14.65 and 4.39 Hz, indole CHH), 3.35 (1H, dd, 5.86 and 13.19 Hz, CNHCHH), 3.45 (1H, dd, 6.35 and 13.43 Hz, CNHCHH), 3.0-3.25 (2H, m, CHH indole and (CH₃)₂CH), 4.47 (1H, m, 5.58-5.65 (1H, m, CNH), 6.05-6.15 (1H, m, CNH),

-66-

6.5 (1H, s, $\text{PhNH}\overset{\text{O}}{\parallel}\text{CNH}$), 6.85-7.04 (1H, m, 1ArH), 7.03 (8H, t, 1.46 Hz, 8ArH),
 7.11 (2H, d, 7.82 Hz, 2ArH), 7.20-7.38 (14H, m, 14ArH), 7.57 (1H, td, 1.71 and
 5 7.81 Hz, ArH), 8.53 (1H, d, 3.17 Hz, pyridyl H).

EXAMPLE 23



2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-imidazol-4-yl)-N-(1-pyridin-2-yl-
 cyclohexylmethyl)-propionamide

10 A mixture of XV (120 mg, 0.15 mmol) in formic acid (5 mL) and DCM
 (50 mL) was stirred at room temperature for 24 hours. The solvents were removed
in vacuo, and the residue was taken up in water (50 mL) and washed with EtOAc.
 The aqueous layer was concentrated *in vacuo* at below 40°C, and the residue was
 taken up in DCM and ether and concentrated *in vacuo* to obtain 23 as a solid
 15 (57.8 mg, 65.4%).

^1H NMR (DMSO): δ 1.05-1.60 (8H, m, cyclohexyl), 1.06 (12H, d, 6.84 Hz,

$[(\text{CH}_3)_2\text{CH}]_2$), 2.10-2.13 (2H, m, cyclohexyl), 2.67-2.72 (1H, m, $\text{CNHCH}\overset{\text{O}}{\parallel}$),
 20 2.80-2.98 (1H, m, $\text{CH}(\text{CH}_3)_2$), 3.0-3.16 (1H, m, $\text{CH}(\text{CH}_3)_2$), 3.18-3.21 (1H, m,
 $\text{CNHCH}\overset{\text{O}}{\parallel}$), 3.31-3.41 (2H, obscured by water peak, CHH imidazole),

-67-

4.384.42 (1H, m, α H), 6.43 (1H, br s, CNH), 6.77 (1H, br s, CNH), 7.08 (2H, d, 7.32 Hz, 2ArH), 7.18-7.21 (2H, m, 2ArH), 7.34 (1H, d, 8.06 Hz, 1ArH),

5

$\begin{array}{c} \text{O} \\ \parallel \end{array}$
7.52-7.69 (2H, m \times 2, CNH, 1ArH), 7.71 (1H, t, 7.81 Hz, 1ArH), 8.56 (1H, d, 4.15 Hz, ArH), 12.00 (1h, br s, indole NH);

10

IR (film): 3291.0, 2929.0, 1733.0, 1645.0, 1589.0, 1539.0, 1471.0, 1362.0, and


1238.0 cm^{-1} ; MS m/e (E1+) 530 (M^+) 531 ($\text{M} + \text{H}^+$);

Analysis for $\text{C}_{31}\text{H}_{42}\text{N}_6\text{O}_2 \cdot 0.7 \text{HCOOH}$; mp 114-116°C; HPLC R.T. = 17.045 and

17.36, C^{18} reverse phase 10% to 80% MeCN:TFA/ H_2O :TFA.

-68-

SCHEME 9



Reagents and Conditions:

- i) p -Nitrophenyl chloroformate, NEt_3 , THF
- 5 ii) 2,6-Diisopropyl phenyl N methyl amine, NEt_3 , toluene, Δ
- iii) LiOH , H_2O , MeOH , Δ
- iv) HBTU, cyclohexyl methyl amine, DIPEA, DMF

Synthesis of Example 24Step 1

To a cooled (0°C) solution of α -Me (R,S) tryptophan methyl ester (2 g, 8.6 mmol) in dry THF (100 mL) was added dropwise p-nitro phenyl chloroformate (1.74 g, 8.6 mmol) followed by triethyl amine (1.2 mL, 8.6 mmol) dropwise. The reaction mixture was warmed to room temperature and stirred for 2 hours. The solution was then taken up in EtOAc and washed with 1N HCl (aq), brine, dried (MgSO₄), and concentrated *in vacuo*. The residue was purified on normal phase silica with a gradient of heptane to 7:3 heptane/EtOAc as eluent to yield XVI (1.85 g, 54%) which was used without further purification in the next step.

Step 2

To a solution of the carbamate XVI (318 mg, 0.8 mmol) in toluene (60 mL) was added N-methyl diisopropyl aniline (XX) (153 mg, 0.8 mmol) followed by triethyl amine (1 mL), and the mixture was refluxed for 9 hours. The mixture was taken up in EtOAc and washed with 1N HCl (aq), brine, NaHCO₃ (aq), dried (MgSO₄), and concentrated *in vacuo*. The residue was purified by normal phase chromatography eluting with a gradient of heptane to 6:4 heptane/EtOAc to yield pure XVII (213 mg, 59.2%).

¹H NMR (CDCl₃): δ 0.77, 0.86, 1.10, 1.14 (12H, 4 \times d, 6.84, 6.59, 7.08, 6.84 Hz, respectively, [(CH₃)₂CH]₂), 1.68 (3H, s, α -CH₃), 2.86 (1H, qⁿ, 6.84 Hz, (CH₃)₂CH), 2.98 (1H, qⁿ, 6.84 Hz, (CH₃)₂CH), 3.03 (1H, d, 14.40 Hz, CHH indole), 3.08 (3H, s, N-CH₃), 3.13 (1H, d, 14.40 Hz, CHH indole), 3.63 (3H, s, CO₂CH₃), 4.68

¹³C NMR (CDCl₃): δ 15.1 (1H, s, N(CH₃)CNH), 6.23 (1H, d, 2.44 Hz, 1ArH), 6.99 (1H, t, 7.08 Hz, 1ArH), 7.09-7.16 (3H, m, 3ArH), 7.25-7.27 (1H, m, ArH), 7.31-7.36 (2H, m, 2ArH), 7.77 (1H, s, indole NH); IR (film): 3280.0, 2963.0, 1737.0, 1650.0, 1508.0, 1459.0, 1343.0, 1256.0, 1105.0, 910.0, and 739.0 cm⁻¹.

-70-

Step 3

To a solution of the ester XVII (151.6 mg, 0.34 mmol) in THF (20 mL) was added lithium hydroxide (529 mg, 12.6 mmol) as a solution in water (30 mL) followed by methanol (10 mL), and the reaction mixture was refluxed for 7 hours. The mixture was concentrated *in vacuo* to remove only the organic solvents, and the aqueous mixture remaining was extracted with ether. The aqueous layer was acidified to pH 1 with HCl (aq) and re-extracted with EtOAc, dried (MgSO₄), and concentrated *in vacuo* to yield pure acid XVIII (105 mg, 71%).


¹H NMR (CDCl₃): δ 0.69 (3H, d, 6.84 Hz, CH₃CH), 0.82 (3H, d, 6.84 Hz, CH₃CH), 1.09 (3H, d, 6.84 Hz, CH₃CH), 1.13 (3H, d, 6.84 Hz, CH₃CH), 1.65 (3H, s, αCH₃), 2.72 (1H, qⁿ, 7.08 Hz, (CH₃)₂CH), 2.79 (1H, qⁿ, 6.59 Hz, (CH₃)₂CH), 2.99 (1H, d, 14.89 Hz, indole CHH), 3.32 (1H, d, 14.89 Hz,

CHH indole), 3.10 (3H, s, N-CH₃), 4.72 (1H, s, NMeCNH), 6.46 (1H, d, 2.69 Hz, indole H2), 6.93 (1H, t, 7.08 Hz, indole H5), 6.99 (1H, t, 4.15 Hz, indole H6), 7.08-7.33 (5H, m, 5ArH), 7.79 (1H, br s, indole NH);

IR (film): 3383.0, 1634.0, 1505.0, and 1053.0 cm⁻¹;

MS m/e (APCI) 436.7 (M + H⁺).

EXAMPLE 24



-71-

N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)-3-methyl-ureido]-3-(1H-indol-3-yl)-2-methyl-propionamide

To a solution of the acid XVIII (104 mg, 0.24 mmol), HBTU (91 mg, 0.24 mmol) and diisopropyl ethyl amine (93 mg, 0.72 mmol) which had been stirred for 10 minutes was added cyclohexyl methyl amine (54 mg, 0.48 mmol), and the mixture was stirred for an hour. The reaction mixture was taken up in EtOAc and washed with 1N HCl (aq), NaHCO₃ (aq), brine, dried (MgSO₄), and concentrated *in vacuo*. The residue was purified by normal phase chromatography eluting with a gradient of heptane to 1:1 heptane/EtOAc to yield pure 24 (56 mg, 45%), mp 214-216°C.

¹H NMR (CDCl₃): δ 0.68, 0.95, 1.11, 1.15 (12H, 4 × d, 7.08 Hz, [(CH₃)₂CH]₂), 0.82-0.93 (2H, m, cyclohexyl), 1.30-1.36 (2H, m, cyclohexyl), 1.56-1.66 (6H, m, cyclohexyl), 1.66 (3H, s, αCH₃), 2.76-2.83 (1H, m, (CH₃)₂CH), 2.78 (1H, d, 14.40 Hz, CHH indole), 2.90 (1H, qⁿ, 6.84 Hz, (CH₃)₂CH), 3.05 (2H, t, 6.10 Hz,

15 $\begin{array}{c} \text{O} \\ \parallel \\ \text{CNHCH}_2 \end{array}$, 3.08 (3H, s, N-CH₃), 3.37 (1H, d, 14.65 Hz, CHH indole), 4.67 (1H, s,

20 $\begin{array}{c} \text{O} \\ \parallel \\ \text{N(CH}_3\text{)CNH} \end{array}$, 6.19 (1H, d, 2.4 Hz, ArH), 6.83 (1H, br t, $\begin{array}{c} \text{O} \\ \parallel \\ \text{CNHCH}_2 \end{array}$), 6.95 (1H, t, 7.81 Hz, ArH), 7.08 (2H, t, 7.57 Hz, 2ArH), 7.16 (1H, d, 7.57 Hz, ArH), 7.23 (1H, d, 8.3 Hz, ArH), 7.31-7.36 (2H, m, 2ArH), 7.73 (1H, br s, indole NH);


IR (film): 3307.0, 2925.0, 1625.0, 1505.0, 1339.0, and 739.0 cm⁻¹; MS m/e (APCI) 531.7 (M + H⁺);

25 Analysis for C₃₃H₄₆N₄O₂, C, H, N; mp 214-216°C; HPLC R.T. = 19.77,

C¹⁸ reverse phase, 40% to 100% MeCN:TFA/H₂O:TFA.

-72-

SCHEME 10



Reagents and Conditions:

- i) DCC, HOBT, amine, DCM
- 5 ii) HCl gas, Et₂O
- iii) 2,6-Diisopropyl phenyl isocyanate, EtOAc, Δ
- iv) Separate diastereoisomers by chromatography

Synthesis of Example 25Step 1

- 10 A solution of BOC(RS)-(α-methyl)tryptophan (3.00 g, 9.4 mmol), (4S,5S)-(+)-5-amino-2,2-dimethyl-4-phenyl-1,3-dioxane (1.95 g, 9.4 mmol), 1-hydroxybenzotriazole hydrate (1.27 g, 9.4 mmol) in dichloromethane (100 mL) was cooled to 0°C and stirred 5 minutes at which time dicyclohexylcarbodiimide

-73-

(1.94 g, 9.4 mmol) was added, and the reaction mixture was stirred 10 days at room temperature. The reaction mixture was concentrated to dryness, taken up in ethyl acetate, washed with 10% aqueous potassium carbonate, saturated aqueous sodium chloride, dried over magnesium sulfate, filtered, and concentrated to a yellow oil. The oil was filtered through silica gel using ethyl acetate as eluant. The product (Intermediate XIX) was obtained as a white foam, 4.70 g.

FAB mass spectrum $(M + H^+)^+ = 508.6$.

Analysis for $C_{29}H_{37}N_3O_5$ (507.63).

Step 2

Anhydrous hydrogen chloride gas was bubbled into a solution of the BOC-amide-acetonide (1.00 g, 2.0 mmol) (Intermediate XIX) for about 3 minutes. The reaction mixture was allowed to stand at room temperature for 3 hours and no starting material remained by tlc. The reaction mixture was concentrated *in vacuo* to a light tan solid. The solid was partitioned between 0.1N sodium hydroxide and ethyl acetate, the ethyl acetate was dried over magnesium sulfate, filtered, and concentrated to a white foam. The white foam was filtered through silica gel using ethyl acetate as eluant. The product (Intermediate XX) was obtained as a white solid, 0.33 g.

E1 mass spectrum $M^+ = 407$.


Parent molecular weight = 407.5.

Analysis calculated for $C_{24}H_{29}N_3O_3 \cdot 0.33 H_2O$, C, H, N.

A by-product of the reaction was the aminodiol 0.25 g. A larger run employing 3.4 g of the BOC-amide-acetonide yielded 2.18 g of the amino acetonide and 0.58 g of the aminodiol.

-74-

EXAMPLE 25



2-[3-(2,6-Diisopropyl-phenyl)-ureido]-N-(2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(1H-indol-3-yl)-2-methyl-propionamide

- 5 A solution of the amino acetone (0.40 g, 0.98 mmol) (Intermediate XX) and 2,6-diisopropyl phenyl isocyanate (0.23 g, 1.13 mmol) in ethyl acetate (30 mL) was briefly heated to achieve solution. The reaction mixture was allowed to stand 2 days at room temperature and was then concentrated to a viscous oil. The oil was chromatographed on silica gel using ethyl acetate as eluant yielding 0.288 g of the
- 10 less polar product (Example 25).

FAB mass spectrum $(M + H^+)^+ = 611.2$.

Analysis for $C_{37}H_{46}N_4O_4 \cdot 0.33 C_4H_8O_2$, C, H, N.


Parent molecular weight = 610.78.

Also obtained was 0.237 g of the more polar product.

- 15 FAB mass spectrum $(M + H^+)^+ = 611.2$.

-75-

EXAMPLE 26



Example 26 was prepared as for Scheme 3 using Intermediate XXI.

Example 26 was isolated in 24.5% yield.

- 5 ^1H NMR (DMSO): δ 1.12-1.55 (8H, mm, cyclohexyl), 1.47 (3H, s, αCH_3),
 1.96-2.03 (2H, m, cyclohexyl), 2.56 (3H, s, N = C- CH_3), 3.06 (1H, dd, J = 5.37
 10 and 13.19 Hz, CNHCHH), 3.27 (1H, dd, J = 6.59 and 13.18 Hz, CNHCHH), 3.40
 (2H, 2 \times d, J = 15.62 and 15.14 Hz, respectively, CHH indole), 6.56 (1H, s,
 15 $\text{NHCNH}\alpha\text{C}$), 6.81 (1H, t, J = 7.81 Hz, indole H-5), 6.95 (1H, d, J = 2.20 Hz,
 indole H-2), 6.98-7.00 (2H, m, indole H-6 and CH -5), 7.28 (1H, d, J = 8.06 Hz,
 20 ArH), 7.43 (1H, d, J = 7.81 Hz, ArH), 7.46 (1H, Bt, J = 5.37 Hz, CNHCH_2),
 7.63 (2H, d, J = 9.28 Hz, p- NO_2 $\text{ArH} \times 2$), 8.16 (2H, d, J = 9.27 Hz, p- NO_2
 $\text{ArH} \times 2$), 9.50 (1H, s, NHCNH), 10.83 (1H, s, indole NH);
 IR (film): 3342.0, 2933.4, 1704.3, 1645.0, 1555.9, 1505.0, 1456.4, 1329.0,
 1112.0 cm^{-1} ;
 MS m/e (ES) 573.05 (M^+), 575.08 ($\text{M}+\text{H}^+$);


-76-

Analysis $C_{30}H_{34}N_6O_4S$: C,H,N;

mp 205-209°C;

HPLC R.T. = 10.85, C^{18} reverse phase, 40% to 100% MeCN:TFA/H₂O:TFA.

EXAMPLE 27



Example 27 was prepared as for Scheme 3 using Intermediate XXII.

Example 27 was isolated in 26.2% yield.

 1H NMR (DMSO): δ 1.03-1.53 (8H, m, cyclohexyl), 1.44 (3H, s, αCH_3),2.10-2.20 (2H, m, cyclohexyl), 3.06 (1H, dd, $J = 5.13$ and 12.94 Hz, $CNHCHH$),3.28 (1H, dd, obscured by water peak, $CNHCHH$), 3.38 (2H, $2 \times d$, $J = 15.14$ Hz,

CHH indole), 3.68 (3H, s, OCH_3), 6.55 (1H, s, $NHCNH\alpha C$), 6.81 (1H, t, $J = 7.08$ Hz indole H-5), 6.94 (1H, d, $J = 1.71$ Hz, indole H2), 6.98 (1H, t, $J = 7.08$ Hz, indole H6), 7.04 (1H, dd, $J = 2.93$ and 8.79 Hz, indole H7), 7.19 (1H, d, $J = 8.79$ Hz,

pyridyl H3), 7.23 (1H, d, $J = 8.3$ Hz, pyridyl H4), 7.41-7.45 (2H, m, $CNHCH_2$ and ArH), 7.62 (2H, d, $J = 9.28$ Hz, p-NO₂ ArH $\times 2$), 8.16 (2H, d, $J = 9.52$ Hz, p-NO₂

-77-

ArH \times 2), 8.17-8.19 (1H, m, ArH), 9.49 (1H, s, NHCNH), 10.82 (1H, s, indole NH);

IR (film): 3355.0, 2925.0, 1652.1, 1558.1, 1504.7, 1453.6, 1328.2, 1052.5 cm^{-1} ;


MS m/e (APCI) 584.1 (M), (M+H⁺) = 585.1;

Analysis C₃₂H₃₆N₆O₅•0.3H₂O: C, H, N;

mp 213-215°C;

HPLC R.T. = 9.81 and 10.40, C¹⁸ reverse phase, 40% to 100% MeCN:TFA/
H₂O:TFA.

EXAMPLE 28



Example 28 was prepared as for Scheme 3 using Intermediate XXIII.

Example 28 was isolated in 48% yield.

¹H NMR (DMSO): δ 1.10-1.23 (3H, m, cyclohexyl), 1.37-1.60 (5H, m, cyclohexyl), 1.40 (3H, s, αCH_3), 1.98-2.08 (2H, m, cyclohexyl), 2.06 (6H, s,

NMe₂), 2.98 (1H, dd, J = 5.62 and 13.43 Hz, CNHCHH), 3.22 (2H, s,

ArCH₂NMe₂), 3.27 (1H, dd, J = 7.08 and 14.16 Hz, CNHCHH), 3.35 (1H, d, J =

-78-

14.65 Hz), CHH indole), 3.40 (1H, d, J = 14.65 Hz, CHH indole), 6.49 (1H, s,

5 $\begin{array}{c} \text{O} \\ \parallel \\ \text{NHCNH}\alpha\text{C} \end{array}$), 6.81 (1H, t, J = 7.81 Hz, indole H5), 6.93 (1H, d, J = 2.2 Hz, indole H-2), 6.98 (1H, t, J = 7.08 Hz, indole H6), 7.05 (2H, d, J = 8.06 Hz, 2 \times ArH), 7.16

10 $\begin{array}{c} \text{O} \\ \parallel \\ \text{CNHCH}_2 \end{array}$), 7.23 (2H, d, J = 8.30 Hz, 2 \times ArH), 7.27 (1H, d, J = 8.06 Hz, indole H7), 7.43 (1H, d, J = 7.81 Hz, indole H4), 7.64 (2H, d, J = 9.28 Hz, p-NO₂ ArH \times 2), 8.18 (1H, d, J = 9.28 Hz, 2 \times p-NO₂ ArH), 9.45 (1H, s,

$\begin{array}{c} \text{O} \\ \parallel \\ \text{NHCNH} \end{array}$), 10.82 (1H, s, indole NH);

IR (film): 3339.0, 2930.8, 1705.3, 1651.2, 1599.0, 1505.0, 1329.0, 1112.0 (cm⁻¹);


15 MS m/e (APCI) 611.2 (M+H⁺);

Analysis C₃₅H₄₂N₆O₄: C, H, N;

mp 200-202°C;

HPLC R.T. = 23.35, C¹⁸ reverse phase, 10% to 80% MeCN:TFA/H₂O:TFA.

EXAMPLE 29



Example 29 was prepared as for Scheme 3 using Intermediate XXIV.

Example 29 was isolated in 70% yield.

-79-

¹H NMR (DMSO): δ 1.10-1.22 (2H, m, piperidino CH's), 1.24-1.42 (4H, m, piperidino CH's), 1.39 (1.5H, s, αMe), 1.43 (1.5H, s, αMe), 2.02-2.16 (2H, m, piperidino CH's), 2.21-2.30 (2H, m, piperidino CH's), 3.22-3.60 (5H, m, indole CH₃ and CONHCH₂CHN), 6.53 (0.5H, s, CONH), 6.57 (0.5H, s, CONH);

5 6.77-6.84 (1H, m, indole H₅), 6.95-7.04 (2H, m, indole H₆ and H₂), 7.12-7.32 (6H, m, indole H₇ and 5 × ArH's), 7.45 (1H, d, J = 8.1 Hz, indole H₄), 7.48-7.63 (1H, m, CONHCH₂), 7.62 (2H, d, J = 9.0 Hz ArHNO₂ ring), 8.14-8.17 (2H, m, ArHNO₂ ring), 9.49 (0.5H, s, CONH), 9.50 (0.5H, s, CONH), 10.84 (0.5H, s, indole NH), and 10.87 (0.5H, s, indole NH);

10 IR (film): 3336.0, 2934.0, 1710.0, 1657.0, 1506.0, 1329.0, 1229.0, 1112.0, and 851.0 cm⁻¹;

MS m/e (ES⁺) 64.2 (20%), 205.2 (37%), 431.1 (12%), 569.2 (M+H⁺, 100%⁺);


mp 133-137°C;

HPLC R.T. = 10.57 and 10.77, C¹⁸ reverse phase, 40% to 100% MeCN:TFA/

15 H₂O:TFA.

-80-

EXAMPLE 30




Example 30 was prepared as for Scheme 3 using Intermediate XXV.

Example 30 was isolated in 83% yield.

- 5 ^1H NMR (DMSO): δ 1.05-1.20 (3H, m, cyclohexyl CH), 1.30-1.42 (5H, m, cyclohexyl CH), 1.47 (3H, s, αCH_3), 1.70-1.90 (2H, m, cyclohexyl CH), 3.00-3.10 (1H, m, CHHNHCO), 3.20-3.28 (1H, m, CHHNHCO), 3.37 (1H, d, 14.4 Hz, CHH indole), 3.45 (1H, d, 14.4 Hz, CHH indole), 6.51 (1H, s, PhNHCONH or CH imidazole), 6.58 (1H, s, PhN , PhNHCONH or CH imidazole), 6.77-6.81 (1H, m, $\text{C}_5\text{-H}$ indole), 6.93-7.04 (8H, m, $6 \times \text{ArH}$, $\text{C}_6\text{-H}$ indole, $\text{C}_2\text{-H}$ indole), 7.19 (1H, s, imidazole CH), 7.27 (1H, d, 7.9 Hz, $\text{C}_7\text{-H}$ indole), 7.32-7.39 (9H, m, ArH), 7.42 (1H, d, 8.1 Hz $\text{C}_4\text{-H}$ indole), 7.56 (2H, d, 9.0 Hz, PhNO_2CH), 7.86 (1H, t, 5.4 Hz, NH amide), 8.07 (2H, d, 9.0 Hz, PhNO_2CH), 9.48 (1H, s, PhNHCO), 10.82 (1H, s, indole NH);
- 10 IR (film) 3335, 3060, 2932, 2855, 1704, 1645, 1599, 1557, 1505, 1446, 1330, 1303, 1230, 1176, 1113, 1039, 1011, 852, and 745 cm^{-1} ;
- MS m/e (APCI): 786.3 ($\text{M}+\text{H}$);
- mp 148-154°C;
- HPLC R.T. = 16.79, C^{18} reverse phase, 40% to 100% $\text{MeCN:TFA/H}_2\text{O:TFA}$ over
- 20 20 minutes.

-81-

EXAMPLE 31



To a stirred solution of Example 30 (0.23 g, 0.29 mmol) in MeOH (50 mL) was added 2N HCl (2 mL). The reaction mixture was refluxed for 2 hours. The solution was neutralized using 1N NaOH and evaporated in vacuo. The residue was purified on reverse phase silica eluting with a gradient of MeOH/H₂O 0% to 100%. The product was eluted with 60% MeOH/H₂O to give Example 31 as a yellow solid (0.073 g, 44%).

¹H NMR (DMSO + DCL/D₂O): δ 1.05-1.25 (3H, m, cyclohexyl CH), 1.35-1.55 (5H, m, cyclohexyl CH), 1.36 (3H, s, α CH₃), 1.90-2.00 (2H, m, cyclohexyl CH), 3.10 (1H, d, 13.2 Hz, CHH-indole or CHH-cyclohexyl), 3.23 (1H, d, 13.4 Hz, CHH indole or CHH-cyclohexyl), 3.28 (2H, s, CH₂-indole or CH₂-cyclohexyl), 6.78-6.80 (1H, m, indole C₅-H), 6.93-6.97 (1H, m, indole C₆-H), 7.01 (1H, s, ArH), 7.24-7.26 (2H, m, indole C₇-H, Ar-H), 7.40 (1H, d, J = 8.1 Hz, indole C₄-H), 7.59-7.61 (2H, m, PhNO₂ CH), 8.11-8.14 (2H, m, PhNO₂ CH), 9.05 (1H, d, 1.0 Hz, CH imidazole);


IR (film): 3356, 2935, 2859, 1699, 1652, 1597, 1557, 1505, 1458, 1331, 1303, 1232, 1208, 1195, 1177, 1112, 851, and 746 cm⁻¹;

MS m/e (ES⁺ high resolution), Measured (M+H)⁺ 544.2677, Expected (M+H)⁺ 544.2672, Deviation (ppm) +0.9;
mp 150-152°C;

-82-


HPLC R.T. = 17.9 min, C¹⁸ reverse phase, 10% to 80% MeCN:TFA/H₂O:TFA over 20 minutes.

EXAMPLE 32



-83-

PREPARATION OF INTERMEDIATE II



Reagents and Conditions:

- i) Sodium hydride, 1,5-dibromopentane, DMSO, Et₂O, 15°C
- 5 ii) Raney nickel, EtOH-NH₃, H₂, 50 psi, 40°C

PREPARATION OF INTERMEDIATES

Synthesis of Intermediate IIStep 1

To a stirred suspension of sodium hydride (60% dispersed in oil) (4 g, 0.1 m) in DMSO (70 mL) under nitrogen at 15°C was added dropwise a solution of 2-pyridyl acetonitrile (6 g, 51 mmol) and 1,5-dibromopentane (6.81 mL, 51 mmol) in ether (40 mL) and DMSO (10 mL) over 1 hour. The mixture was allowed to warm to room temperature and stirred for a further 24 hours under nitrogen. The reaction mixture was carefully quenched by the addition dropwise of isopropanol (10 mL), followed by water (100 mL) 10 minutes later. The reaction solution was taken up in EtOAc and washed with water. The aqueous layer was re-extracted with EtOAc, and the two organic layers were combined, dried (MgSO₄), and concentrated *in vacuo*. The residue was purified on silica with a gradient of

10

15

-84-

heptane to 9:1 heptane/EtOAc to give 1-cyano-1-(2-pyridyl) cyclohexane (6.77 g, 72%).


^1H NMR (CDCl_3): δ 1.77-2.17 (10H, 2 \times m, cyclohexyl), 7.20-7.27 (1H, m, pyridyl H), 7.60-7.62 (1H, m, pyridyl H), 7.70-7.73 (1H, m, pyridyl H), 8.4-8.42 (1H, m, pyridyl H).

Intermediate II

Raney nickel (8 g) was washed with water to obtain pH 7 and then washed with ethanol to remove water (ensuring the catalyst was moist at all times). The Raney nickel was taken up in ethanolic ammonia (100 mL) and 1-cyano-1-(2-pyridyl) cyclohexane (6.7 g, 0.036 m) was added to the mixture which was then shaken on a Parr hydrogenation apparatus under 50 psi of hydrogen at 40°C for 22 hours. The reaction mixture was filtered through Celite and concentrated *in vacuo* to give pure II as a clear oil (6.89 g, 100%).

^1H NMR: δ 1.20-1.65 (10H, m, cyclohexyl), 2.20-2.36 (2H, m, CH_2NH_2), 2.70-2.90 (2H, br s, NH_2), 7.00-7.20 (1H, m, ArH), 7.3-7.4 (1H, m, ArH), 7.6-7.73 (1H, m, ArH), 8.6-8.7 (1H, m, ArH).

PREPARATION OF INTERMEDIATE III



Reagents and Conditions:

- i) DEAD, PPh_3 , $(\text{PhO})_2\text{PON}_3$, THF
- ii) Lindlar, EtOH

-85-

Synthesis of Intermediate IIIStep 1

A solution of diphenylposphonylazide (473 mg, 1.72 mmol) in THF (10 mL) was added dropwise over 20 minutes to a stirred solution of 1R,2S,trans-2-phenyl-1-cyclohexanol (303 mg, 1.72 mmol), triphenylphosphene (451 mg, 1.72 mmol), and diethyl ozodicarboxylate (300 mg, 1.72 mmol) in dry THF (10 mL) at room temperature. The resulting mixture was stirred for 3 days, then the solvent removed *in vacuo*. The product was purified by chromatography (silica, 10-20% ethyl acetate in heptane) to leave a clear oil A (217 mg, 63%).

^1H , NMR (CDCl_3): 1.34-2.4 (8H, m, $4 \times \text{CH}_2$), 2.76-2.80 (1H, m, CH), 3.94 (1H, d, $\text{CH}-\text{N}_3$, $J = 2.8$ Hz), 7.22-7.34 (5H, m, Ph);

IR (film): 3028, 2984, 2860, 2103, 1602, 1486, 1447, and 1267; $[\alpha]_{\text{D}}^{18} + 81.4^\circ$ ($c = 1.05$, acetone).

Step 2

A (1.89 mg, 0.84 mmol) was hydrogenated in absolute ethanol (50 mL) at 30°C and 45 psi over Lindlar catalyst (25 mg). The catalyst was filtered off and the solvent removed to yield an oil (130 mg, 79%).


^1H NMR (CDCl_3): 1.01 (2H, bs, NH_2), 1.35-2.06 (8H, m, $4 \times \text{CH}_2$), 2.77-2.83 (1H, m, CH), 3.24-3.26 (1H, m, CHCH_2), 7.20-7.34 (5H, m, Ph);

IR (film): 3360, 3060, 3025, 2927, 2855, 1601, 1582, 1495, and 1447;

$[\alpha]_{\text{D}}^{21} + 72.9^\circ$ ($c = 1.04$, methanol).

-86-

PREPARATION OF INTERMEDIATE XXI



Reagents and Conditions:

- (i) (a) EtOAc, NaHCO₃ (aq); (b) 95% Ethanol, water, potassium cyanide
 5 reflux
 (ii) Sodium hydride, 1,5-dibromopentane, DMSO, Et₂O, room temperature, Ar
 (iii) Raney Nickel, EtOH-NH₃, H₂, 50 psi, 35°C

Synthesis of Intermediate XXIStep 1

- 10 4-Chloromethyl-2-methyl thiazole hydrochloride (1 g, 5.4 mmol) was taken
 up in sodium bicarbonate saturated aqueous solution and extracted with EtOAc,
 dried (MgSO₄), and concentrated in vacuo. The residue was dissolved in 95%
 ethanol (50 mL) and potassium cyanide (353 mg, 5.4 mmol) followed by water
 (5 mL) were added to the reaction mixture. The mixture was refluxed for 18 hours
 15 and cooled to room temperature. The reaction mixture was taken up in EtOAc and
 washed with water, dried (MgSO₄), and concentrated in vacuo. The residue was

-87-

purified on silica with a gradient of heptane to 1:1 heptane/EtOAc to give 4-cyanomethyl-2-methyl thiazole (180 mg, 24%).

^1H NMR (CDCl_3): δ 2.71 (3H, s, CH_3), 3.85 (2H, s, CH_2CN), 7.13 (1H, s, ArH);

IR (film): 2923.0, 2863.7, 2255.6, 1525.0, 1412.0, 1261.0, 1101.0, 1020.0, and
5 799.0 cm^{-1} ;

MS m/e (ES^+) 139.06 ($\text{M}+\text{H}^+$).

Step 2 As for Intermediate II, Step 1

1-Cyano-1-(2-methyl thiazol-4-yl)cyclohexane isolated in 100% yield.

^1H NMR (CDCl_3): δ 1.70-2.00 (8H, mm, cyclohexyl), 2.12-2.20 (2H, m,
10 cyclohexyl), 2.70 (3H, s, CH_3), 7.12 (1H, s, ArH);

IR (film): 2929.0, 2858.7, 1453.1, and 1227.0 cm^{-1} ;

MS m/e (APCI) 207.12 ($\text{M}+\text{H}^+$) (100%).

Step 3 As for Intermediate II, Step 2

Intermediate XXI, 1-aminomethyl-1-(2-methyl thiazol-4-yl)cyclohexane was
15 isolated in 98% yield.


^1H NMR (CDCl_3): δ 1.68-2.00 (8H, mm, cyclohexyl), 2.03-2.20 (4H, mm,
2 \times cyclohexyl H, NH_2), 2.69 (2H, s, CH_2NH_2), 2.70 (3H, s, CH_3), 7.12 (1H, s,
ArH);

IR (film): 2927.0, 2857.0, 2237.0, 1667.0, 1515.0, 1453.0, 1376.0, 1185.0, 1169.0,
20 1141.0, 957.0, and 745.0 cm^{-1} ;

MS m/e (APCI) 211.15 ($\text{M}+\text{H}^+$), 207.13 (100%).

-88-

PREPARATION OF INTERMEDIATE XXII



Reagents and Conditions:

- (i) Sodium hydride, methyl iodide, DMF, 0°C-room temperature under argon
- 5 (ii) M-chloro-peroxy-benzoic acid, sodium sulphate, DCM, room temperature
- (iii) Acetic anhydride, reflux
- (iv) Potassium hydroxide, methanol, reflux
- (v) Thionyl chloride, DCM, reflux
- (vi) Potassium cyanide, 95% ethanol, water, reflux
- 10 (vii) Sodium hydride, 1,5-dibromopentane, DMSO, Et₂O, room temperature, Ar
- (viii) Raney Nickel, EtOH-NH₃, H₂, 57 psi, 35°C

Synthesis of Intermediate XXIIStep 1

To a stirred suspension of sodium hydride (60% dispersed in oil) (1.8 g,
 15 45 mmol) in DMF (60 mL) at 0°C under argon was added a solution of 2-hydroxy-

-89-

5-methyl-pyridine (4.91 g, 45 mmol) in DMF (60 mL). Effervescence was observed, and the reaction mixture was allowed to warm to 18°C. Methyl iodide (2.8 mL, 45 mmol) was added to the reaction mixture which was allowed to warm to room temperature and stirred for 1 hour. The reaction mixture was quenched by the addition of isopropanol (20 mL), followed by water (20 mL) 30 minutes later, under argon. The reaction mixture was taken up in EtOAc and washed with NaHCO₃ (aq), dried (MgSO₄), and concentrated in vacuo to give 2-methyl-5-methoxy-pyridine as a pure volatile liquid (2.93 g, 53%).

¹H NMR (CDCl₃): δ 2.49 (3H, s, CH₃-C), 3.83 (3H, s, OCH₃), 7.05-7.13 (2H, mm, pyridyl H4 and 5), 8.19 (1H, d, J = 2.8 Hz, pyridyl H2);
IR (film): 2924.0, 2854.0, 1575.0, 1497.0, 1464.0, 1378.0, 1270.0, 1243.0, 1211.0, and 1034.0 cm⁻¹.

Step 2

To a solution of 2-methyl-5-methoxy-pyridine (2.93 g, 24 mmol) in DCM (100 mL) was added sodium sulphate (5 g, 35 mmol), followed by m-chloroperoxy-benzoic acid (10 g, 58 mmol), and mixture was stirred at room temperature for ~48 hours. The reaction mixture was filtered, and the white solid was washed with DCM. The filtrate was concentrated and purified by normal phase chromatography eluting with a gradient of 1:1 EtOAc/heptane to EtOAc to give 2-methyl-5-methoxy-pyridine-N-oxide (2.41 g, 72%).

¹H NMR (DMSO): δ 2.27 (3H, s, C-CH₃), 3.79 (3H, s, OCH₃), 6.96 (1H, dd, J = 2.4 and 8.8 Hz, pyridyl H5), 7.36 (1H, d, J = 8.8 Hz, pyridyl H4), 8.08 (1H, d, J = 2.4 Hz, pyridyl H2);
IR (film): 3386.0, 1616.0, 1566.0, 1516.0, 1452.0, 1375.0, 1304.0, 1197.0, 1172.0, 1131.0, 1030.0, 996.0, and 960.0 cm⁻¹;
MS m/e (ES) 140 (M+H⁺).

Step 3

A mixture of 2-methyl-5-methoxy-pyridyl-N-oxide (1.082 g, 7.8 mmol) and acetic anhydride (excess, 5 mL) was gently warmed to reflux for 10 minutes. The

-90-

reaction mixture was allowed to cool to room temperature before being taken up in EtOAc, washed (NaHCO₃ (aq)), dried (MgSO₄), and concentrated in vacuo to give crude 2-acetoxy-methyl-5-methoxy-pyridine which was taken through to the next step without further purification.

5
$$\begin{array}{c} \text{O} \\ \parallel \\ \text{CH}_2\text{OC} \end{array}$$

¹H NMR (CDCl₃): δ 2.13 (3H, s, OC $\underline{\text{CH}}_3$), 3.87 (3H, s, $\underline{\text{CH}}_3\text{O}$), 5.16 (2H, s,
 10 $\underline{\text{CH}}_2\text{OC}$), 7.20 (1H, dd, J = 3.2 and 8.8 Hz, pyridyl $\underline{\text{H}}$), 7.30 (1H, d, J = 8.4 Hz, pyridyl $\underline{\text{H}}$), 8.30 (1H, d, J = 3.2 Hz, pyridyl $\underline{\text{H}}$);
 IR (film): 2943.0, 1740.0, 1576.0, 1499.0, 1377.0, 1293.0, 1227.0, and
 1029.0 cm⁻¹;
 MS m/e (ES) 182.16 (100%) (M+H⁺).

15 Step 4

To a stirred solution of 2-acetoxy-methyl-5-methoxy-pyridine (1.41 g, 7.8 mmol) in methanol (30 mL) was added excess potassium hydroxide (1.6 g), and the mixture was refluxed for 2 hours. The solvent was removed in vacuo, and the residue was purified by column chromatography eluting with a heptane to ethyl acetate gradient. The extremely volatile 2-hydroxy-methyl-5-methoxy-pyridine was
 20 obtained as a solution in ethyl acetate (0.68 g, 63% yield).

¹H NMR (CDCl₃): δ 3.87 (3H, s, O $\underline{\text{CH}}_3$), 4.70 (2H, s, $\underline{\text{CH}}_2\text{OH}$), 7.18-7.24 (2H, m, pyridyl H4 and 5), 8.25 (1H, d, J = 2.8 Hz, pyridyl H2);
 IR (film): 3346.0, 1575.0, 1499.0, 1271.0, 1210.0, and 1028.0 cm⁻¹;
 25 MS m/e (ES) 140.18 (M+H⁺).

Step 5

To a solution of 2-hydroxy-methyl-5-methoxy-pyridine (0.68 g, 4.9 mmol) in dry DCM was added dropwise excess thionyl chloride (2.0 mL), and the mixture was refluxed for 2 hours. The solvent was removed in vacuo, and the residue was
 30 taken up in EtOAc and washed with NaHCO₃ (aq), dried (MgSO₄, and

-91-

concentrated in vacuo. The extremely volatile 2-chloromethyl-5-methoxy-pyridine was obtained as a solution in ethyl acetate to give (984.0 mg, 83.5%) yield.

^1H NMR (CDCl_3): δ 3.87 (3H, s, OCH_3), 4.65 (2H, s, CH_2Cl), 7.21 (1H, dd, J = 2.8 and 8.4 Hz, pyridyl H4), 7.39 (1H, d, J = 8.4 Hz, pyridyl H5), 8.27 (1H, d, J = 2.8 Hz, pyridyl H2);

IR (film): 3337.1, 2930.0, 2854.7, 1731.3, 1639.5, 1537.9, 1423.2, 1301.9, and 1158.0 cm^{-1} ;

MS m/e (ES) 158.15 ($\text{M}+\text{H}^+$) (100%).

Step 6 As for Intermediate XXI, Step 1

2-Cyanomethyl-5-methoxy-pyridine was isolated in 73% pure yield.

^1H NMR (CDCl_3): δ 3.87 (3H, s, OCH_3), 3.88 (2H, s, CH_2CN), 7.22 (1H, dd, J = 3.2 and 8.8 Hz, pyridyl H4), 7.34 (1H, dd, J = 0.4 and 8.4 Hz, pyridyl H5), 8.27 (1H, d, J = 2.8 Hz, pyridyl H2);

IR (film): 2922.8, 1575.5, 1496.0, and 1271.5 cm^{-1} ;

MS m/e (APCI) 149.18 ($\text{M}+\text{H}^+$) (100%).

Step 7 As for Intermediate II, Step 1

-1-Cyano-1-(4-methoxypyrid-2-yl)cyclohexane was isolated in 60% yield.

NMR (CDCl_3): δ 1.76-2.12 (10H, mm, cyclohexyl), 3.87 (3H, s, OCH_3), 7.21 (1H, dd, J = 2.8 and 8.8 Hz, pyridyl H4), 7.51 (1H, dd, J = 0.8 and 9.6 Hz, pyridyl H5), 8.29 (1H, d, 3.2 Hz, pyridyl H2);

IR (film): 2935.0, 2863.7, 1575.0, 1478.0, 1299.0, 1269.0, 1244.0, and 1017.0 cm^{-1} ;

MS m/e (ES) 217.16 ($\text{M}+\text{H}^+$).

Step 8 As for Intermediate II, Step 2

Intermediate XXII, 1-amino-methyl-1-(4-methoxy-pyrid-2-yl)cyclohexane was isolated in 82% yield.

-92-


^1H NMR (DMSO): δ 1.13-1.58 (8H, mm, cyclohexyl), 2.14-2.22 (2H, m, cyclohexyl), 2.56 (2H, s, NH_2CH_2), 3.80 (3H, s, OCH_3), 7.30 (2H, m, pyridyl H4 and H5), 8.26 (1H, m, pyridyl H2);

IR (film): 2925.0, 2858.6, 1569.4, and 1477.8 cm^{-1} ;

5 MS m/e (APCI) 221.14 ($\text{M}+\text{H}^+$).

-93-

PREPARATION OF INTERMEDIATE XXIII



Reagents and Conditions:

- 5 (i) N-Bromo-succinimide, benzoyl peroxide, carbon tetrachloride, room temperature under argon
- (ii) Dimethyl amine, DCM, room temperature
- (iii) Raney Nickel, EtOH·NH₃, 50 psi, 30°C

Synthesis of Intermediate XXIIIStep 1

- 10 To a solution of 1-(4-methyl-phenyl)-1-cyclohexyl-carbonitrile (2 g, 0.01 m) in CCl₄ (20 mL) under argon at room temperature was added N-bromo-succinimide (1.96 g, 0.011 m) followed by benzoyl peroxide (30% water) (2.3 mg, 1.6 mmol) in CCl₄ (10 mL), and the reaction mixture was refluxed for 5 hours.
- 15 The mixture was cooled to room temperature, filtered, washed with DCM, and concentrated in vacuo. The residue was purified by normal phase chromatography

-94-

eluting with a gradient of heptane to 10% EtOAc:heptane to give the bromide (2.57 g, 92%).

^1H NMR (CDCl_3): δ 1.71-1.86 (8H, mm, cyclohexyl), 2.14 (2H, d, $J = 11.96$ Hz, cyclohexyl), 4.49 (2H, s, $\text{CH}_2\text{-Br}$), 7.41 (2H, d, $J = 8.54$ Hz, 2ArH), 7.47 (2H, d, $J = 8.06$ Hz, 2ArH);

IR (film): 2936.0, 2860.0, 2232.0, 1914.0, 1789.0, 1765.0, 1610.0, 1515.0, 1451.0, 1415.0, 1355.0, and 1231.0 cm^{-1} .

Step 2

To a stirred solution of 1-(4-bromomethyl-phenyl)-1-cyclohexyl-carbonitrile (0.89 g, 3.2 mmol) in DCM (30 mL) under argon at room temperature was added dimethylamine (2 M in THF) (6.42 mL, 12.8 mmol), and the reaction mixture was stirred for 20 hours at room temperature. 1N NaOH (aq) (15 mL) was added to the reaction mixture, and the solution was stirred for 10 minutes. The reaction mixture was taken up in water and extracted with DCM, dried and concentrated in vacuo. The residue was purified on silica (normal phase) eluting with a gradient of heptane to ethyl acetate to give the dimethylamine in 76% yield (593 mg).

^1H NMR (CDCl_3): δ 1.72-1.88 (8H, m, cyclohexyl), 2.15 (2H, d, $J = 11.71$, cyclohexyl), 2.24 (6H, s, $\text{N}(\text{CH}_3)_2$), 3.4 (2H, s, CH_2NMe_2), 7.32 (2H, d, $J = 8.3$ Hz, 2ArH);

IR (film): 3375.0, 2932.9, 2859.7, 1645.8, 1455.6, and 1042.0 cm^{-1} ;

MS m/e (APCI) 243.2 ($\text{M}+\text{H}^+$).

Step 3 As for Intermediate II, Step 2

Intermediate XXIII, 1-aminomethyl-1-[4-(N,N-dimethylaminomethyl)-phenyl]cyclohexane was isolated in quantitative yield.

^1H NMR (CDCl_3): δ 1.22-1.63 (8H, mm, cyclohexyl), 2.07-2.17 (2H, m, cyclohexyl), 2.25 (6H, s, $\text{N}(\text{CH}_3)_2$), 2.68 (2H, s, CH_2NH_2), 3.41 (2H, s, $\text{ArCH}_2\text{NMe}_2$), 7.27 (4H, $2 \times \text{d}$, $J = 6.8$ Hz, $4 \times \text{ArH}$);


-95-

IR (film): 2931.0, 2856.0, 2814.0, 2766.0, 1513.0, and 1455.0 cm^{-1} ;

MS m/e (ES) 247 ($\text{M}+\text{H}^+$).

-96-

PREPARATION OF INTERMEDIATE XXIV



Reagents and Conditions:

(i) Lithium aluminum hydride/aluminum chloride, Et₂O THF 0°C

5

Synthesis of Intermediate XXIVStep 1

To an ice-cold solution of Et₂O (30 mL) under nitrogen was added aluminum chloride (0.5 g, 3.74 mmol), with stirring, over 2 minutes. This solution was added to an ice-cold solution of lithium aluminum hydride, 1 M in Et₂O (3.74 mL, 3.74 mmol) in anhydrous THF (50 mL) stirring under nitrogen. The reducing solution was allowed to warm to room temperature before gradually adding alpha-(1-piperidino)phenylacetonitrile (0.75 g, 3.74 mmol) dissolved in THF (20 mL). The reaction mixture was stirred for 3 hours before cooling and adding a 1:1 mixture of H₂O/THF. Fifty percent aqueous potassium hydroxide (20 mL) was added producing two layers. The organic layer was separated, dried (K₂CO₃), and concentrated in vacuo. The residue was purified on silica eluting with a gradient of DCM to 25% MeOH/DCM to give pure XXIV as a white oil (0.47 g, 62%).

¹H NMR (CDCl₃): δ 1.28-1.40 (2H, m, piperidino CH's), 1.48-1.63 (4H, m, piperidino CH's), 2.17-2.51 (6H, m, NH₂ and 4 piperidino CH's), 2.99-3.04 (1H, m, CHCHNH₂), 3.19-3.24 (1H, m, CHCHNH₂), 3.45-3.48 (1H, m, CHCH₂NH), 7.20-7.37 (5H, m, ArH);


-97-

IR (film): 2932.0, 2853.0, 2804.0, 1492.0, 1452.0, 1158.0, 1104.0, and 765.0 cm⁻¹;

MS m/z (ES+) 205.2 (M+H⁺, 100%).

-98-

PREPARATION OF INTERMEDIATE XXV



Reagents and Conditions:

- (i) Triphenylmethylchloride, triethylamine, DMF, room temperature
- 5 (ii) Sodium hydride, 1,5-dibromopentane, DMSO, room temperature
- (iii) Lithium aluminum hydride/aluminum chloride, Et₂O, THF, 0°C

Synthesis of Intermediate XXVStep 1

To a stirred solution of 4-cyanomethylimidazole (2.24 g, 20.9 mmol) in DMF (50 mL) was added triphenylmethylchloride (6.42 g, 23.0 mmol) and triethylamine (2.12 g, 20.9 mmol). The reaction mixture was stirred at room temperature overnight. The DMF was evaporated in vacuo and the residue taken up in ethyl acetate (100 mL). The resulting white solid was filtered off and discarded. The filtrate was evaporated in vacuo and purified on silica with a gradient of heptane to 2:5 heptane/EtOAc to give the desired product (6.52 g, 89%).

10

15

-99-

¹H NMR (CDCl₃): δ 3.69 (2H, s, CH₂N), 6.84 (1H, d, 1.0 Hz, imidazole CH),

7.10-7.15 (6H, m, 6 ArH), 7.32-7.37 (9H, m, 9 ArH), 7.41 (1H, d, 1.5 Hz,

imidazole CH);

IR (film): 3059, 1597, 1493, 1445, 1412, 1240, 1187, 1156, 1120, 1087, 1037, 991,

5 907, 871, and 751 cm⁻¹;

Analysis C₂₄H₁₉N₃: C, H, N;

mp 139-142°C.

Step 2 As for Intermediate II, Step 1

The desired compound was isolated in 63% yield.

10 ¹H NMR (CDCl₃): δ 1.20-1.35 (1H, m, cyclohexyl CH), 1.65-1.90 (7H, m, cyclohexyl CH), 2.13-2.18 (2H, m, cyclohexyl CH), 6.82 (1H, d, 1.5 Hz, imidazole CH), 7.09-7.50 (6H, m, ArH), 7.30-7.36 (9H, m, ArH), 7.39 (1H, d, 1.0 Hz, imidazole CH);

IR (film): 3060, 2934, 2859, 2233, 1492, 1446, 1161, 1134, 1036, 974, 907, 832,
15 and 747 cm⁻¹;

MS (ES⁺) 418.5 (M⁺+H);

Analysis C₂₉H₂₇N₃: C, H, N;

mp 184-186°C.

Step 3 As for Intermediate XXIV, Step 1

20 The Intermediate XXV was isolated in 73% yield.

¹H NMR (CDCl₃): 1.10-1.70 (2H, br s, NH₂), 1.26-1.52 (8H, m, cyclohexyl CH), 1.95-1.99 (2H, m, cyclohexyl CH), 2.67 (2H, s, CH₂NH₂), 6.54 (1H, d, 1.6 Hz, imidazole CH), 7.12-7.17 (6H, m, ArH), 7.31-7.35 (9H, m, ArH), 7.41 (1H, d, 1.6 Hz, imidazole CH);


25 IR (film): 3374, 3059, 2927, 2852, 1598, 1493, 1445, 1324, 1231, 1184, 1118, 1087, 1036, 906, 870, 825, and 747 cm⁻¹.

-100-

CLAIMS


What is claimed is:

1. A compound of Formula I




- 5 or a pharmaceutically acceptable salt thereof wherein
 Ar is phenyl or pyridyl unsubstituted or substituted by from 1 to
 3 substituents selected from alkyl, halogen, alkoxy, nitro, amino,
 NH₂CH₂-, cyano, CF₃, -NHCONH₂, and CO₂R¹;
 R¹ is hydrogen or straight, branched, or cyclic alkyl of from 1 to 7 carbon
 10 atoms;
 R⁸ is hydrogen or forms a ring with R¹ of from 3 to 7 carbon atoms;
 R² is hydrogen or straight, branched, or cyclic alkyl of from 1 to 8 carbon
 atoms;
 R⁹ is hydrogen or forms a ring of from 3 to 7 carbon atoms with R²;
 15 Ar¹ can be independently selected from Ar and can also include pyridyl-N-
 oxide, indolyl, pyridyl, and imidazole;
 R⁴, R⁵, R⁶, and R⁷ are each independently selected from hydrogen and
 methyl;
 R³ can be independently selected from Ar or is hydrogen, hydroxy, NMe₂,
 20 N-methyl-pyrrole,

-101-



2. A compound according to Claim 1 wherein
 Ar is phenyl unsubstituted or substituted with 1 or 2 substituents selected
 5 from isopropyl, chloro, nitro, and cyano;
 R² forms a ring of from 5-7 carbon atoms with R⁹;
 R⁴, R⁵, and R⁶ are hydrogen;
 R⁷ is methyl or hydrogen; R³ is 2-pyridyl or hydroxy; and
 Ar¹ is indolyl, pyridyl, pyridyl-N-oxide, and imidazolyl.
- 10 3. A compound according to Claim 1 wherein
 Ar is unsubstituted phenyl;
 R¹ is cyclopentyl or tert-butyl;
 R⁴ and R⁵ are hydrogen;
 R⁷ is methyl;
 15 R⁶ is hydrogen;
 R³ is phenyl with two isopropyl substituents, unsubstituted phenyl, or



4. A compound according to Claim 1 wherein
 Ar is 2,6-diisopropyl-phenyl, 4-nitrophenyl, and 4-cyanophenyl;

-102-




R^4 , R^5 , and R^6 are hydrogen;

R^7 is methyl;

R^2 is hydrogen or forms a ring of 6 carbon atoms with R^9 ;

R^3 is hydroxyl,

2-pyridyl,



and Ar^1 is indolyl, pyridyl-N-oxide, pyridyl.

5. A compound according to Claim 1 and selected from:

N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-propionamide;

N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-N-methyl-propionamide;

N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)-1-methyl-ureido]-3-(1H-indol-3-yl)-propionamide.

6. A compound according to Claim 4 and selected from:

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-2-methyl-3-(1-oxy-pyridin-2-yl)-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide; and

-103-

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-2-methyl-3-pyridin-2-yl-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide.

7. A compound according to Claim 1 and selected from:

5 N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)ureido]-3-(1H-indol-3-yl)-2-methyl-propionamide;

N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)ureido]-3-(1H-indol-3-yl)-N-methyl-propionamide;

N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)-3-methyl-ureido]-3-(1H-indol-3-yl)-2-methyl-propionamide;

10 N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)-1-methyl-ureido]-3-(1H-indol-3-yl)-propionamide;

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-2-methyl-3-(1-oxy-pyridin-2-yl)-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide;

15 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-2-methyl-3-pyridin-2-yl-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide;

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-2-methyl-N-(1-pyridin-2-yl-cyclohexylmethyl)-3-(2-trifluoromethyl-phenyl)-propionamide;

2-Methyl-3-(2-nitro-phenyl)-2-[3-(4-nitro-phenyl)-ureido]-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide;

20 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-imidazol-4-yl)-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide;

N-Cyclohexylmethyl-2-[3-(2,6-dimethoxy-phenyl)ureido]-3-(1H-indol-3-yl)-2-methyl-propionamide;

25 3-(1H-Indol-3-yl)-2-methyl-2-{3-[1-(4-nitro-phenyl)-ethyl]-ureido}-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide;

3-(1H-Indol-3-yl)-2-methyl-2-[3-(4-nitro-phenyl)-ureido]-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide;

4-(3-{2-(1H-Indol-3-yl)-1-methyl-1-[(1-pyridin-2-yl-cyclohexylmethyl)-carbamoyl]-ethyl}-ureido)-benzoic acid ethyl ester;

30 3-(1H-Indol-3-yl)-2-methyl-N-(1-pyridin-2-yl-cyclohexylmethyl)-2-[3-(4-trifluoromethylphenyl)-ureido]-propionamide;

-104-

2-[3-(4-Cyano-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide

N-Cyclohexylmethyl-3-(1H-indol-3-yl)-2-methyl-2-[3-(4-nitro-phenyl)-ureido]-propionamide; and

5 N-(1-Hydroxy-cyclohexylmethyl)-3-(1H-indol-3-yl)-2-methyl-2-[3-(4-nitro-phenyl)-ureido]-propionamide.

8. A compound according to Claim 1 and named:

(S)-N-(2,6-Diisopropyl-phenyl)-2-[3-(2,2-dimethyl-1-phenyl-propyl)-ureido]-3-(1H-indol-3-yl)-propionamide.

10 9. A compound according to Claim 1 and selected from:

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-N-(2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(1H-indol-3-yl)-2-methyl-propionamide;

N-(2-Cyclohexyl-ethyl)-2-[3-(2,6-diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-propionamide;

15 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-propionamide:

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-(1,2,3,4-tetrahydro-naphthalen-1-yl)-propionamide;

20 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-(2-phenyl-cyclohexyl)-propionamide;

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-N-indan-1-yl-3-(1H-indol-3-yl)-2-methyl-propionamide; and

2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide.

25 10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1 in combination with a pharmaceutically acceptable carrier.

-105-

11. A method of antagonizing the effects of neuromedin B and/or gastrin-releasing peptide at bombesin receptors which comprises administering a compound according to Claim 1 to a patient.
12. A method of treating depression in a patient in need of said treatment
5 comprising administering a therapeutically effective amount of a compound according to Claim 1.
13. A method of treating seasonal affective disorders in a patient in need of said treatment comprising administering a therapeutically effective amount of a compound according to Claim 1.
- 10 14. A method of treating feeding disorders in a patient in need of said treatment comprising administering a therapeutically effective amount of a compound according to Claim 1.
- 15 15. A method of treating gastrointestinal disorders in a patient in need of said treatment comprising administering a therapeutically effective amount of a compound according to Claim 1.
16. A method of treating sleeping disorders in a patient in need of said treatment comprising administering a therapeutically effective amount of a compound according to Claim 1.
- 20 17. A method of treating memory impairment in a patient in need of said treatment comprising administering a therapeutically effective amount of a compound according to Claim 1.
18. A method of treating cancer in a patient in need of said treatment comprising administering a therapeutically effective amount of a compound according to Claim 1.

-106-

19. A method of treating small cell lung carcinoma in a patient in need of said treatment comprising administering a therapeutically effective amount of a compound according to Claim 1.

5 20. A method of treating psychoses in a patient in need of said treatment comprising administering a therapeutically effective amount of a compound according to Claim 1.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/13871

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D401/12 A61K31/395 C07D209/20 C07D213/89 C07D213/40
C07D213/56 C07D405/12 C07D417/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 200 408 A (NICOLE BRU-MAGNIEZ ET AL) 6 April 1993 * example 17,23,24,27-40,42,43,45,58 *	1
X	EP 0 415 413 A (WARNER-LAMBERT COMPANY) 6 March 1991 see examples 61,63 --- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 December 1997

Date of mailing of the international search report

14.01.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/US 97/13871

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 51, no. 11, 10 June 1957 Columbus, Ohio, US; abstract no. 8074g, K. SCHÖGL ET AL: "The cyclization of histidine derivatives ..." XP002050617 * RN 112274-88-1 * see abstract & MONATSH., vol. 87, - 1956 pages 679-694, ---	1
X	E. SARTORI ET AL: "Synthesis and analgesic ..." EUR. J. MED. CHEM., vol. 29, - 1994 pages 431-439, XP002050615 see table III ---	1
X	ARMAND G.S. BLOMMAERT ET AL: "Cholecystokinin peptidomimetics ..." JOURNAL OF MEDICINAL CHEMISTRY., vol. 36, no. 20, - 1993 WASHINGTON US, pages 2868-2877, XP002050616 * compound 19 * ---	1
X	WO 94 04494 A (WARNER-LAMBERT COMPANY) 3 March 1994 * example 19, step 7 * ---	1
X	WO 93 01169 A (MERCK SHARP & DOHME LTD.) 21 January 1993 see example 31 -----	1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/ 13871

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 11-20
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/13871

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5200408 A	06-04-93	FR 2687147 A	13-08-93
EP 415413 A	06-03-91	US 5153226 A	06-10-92
		AU 640680 B	02-09-93
		AU 6190190 A	07-03-91
		CA 2024300 A	01-03-91
		CN 1050376 A	03-04-91
		JP 3148247 A	25-06-91
WO 9404494 A	03-03-94	AU 5005593 A	15-03-94
		EP 0655055 A	31-05-95
		JP 8500361 T	16-01-96
		NZ 255721 A	24-06-97
		US 5594022 A	14-01-97
WO 9301169 A	21-01-93	CA 2110514 A	21-01-93
		EP 0593559 A	27-04-94
		JP 6509087 T	13-10-94
		US 5472978 A	05-12-95
		AT 133657 T	15-02-96
		AT 133658 T	15-02-96
		AU 664188 B	09-11-95
		AU 2244092 A	11-02-93
		CA 2110513 A	21-01-93
		CA 2110725 A	21-01-93
		DE 69208088 D	14-03-96
		DE 69208089 D	14-03-96
		EP 0522808 A	13-01-93
		EP 0593557 A	27-04-94
		EP 0593615 A	27-04-94
		WO 9301159 A	21-01-93
		WO 9301160 A	21-01-93
		WO 9301165 A	21-01-93
		IE 72090 B	12-03-97
		JP 6509332 T	20-10-94
		JP 6509090 T	13-10-94
		US 5610183 A	11-03-97
		US 5629347 A	13-05-97
		US 5495047 A	27-02-96

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/29592

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D405/12 C07D405/14 C07D413/12 C07D403/12 C07D409/12
C07D401/12 C07D209/20 C07D307/81 A61K31/405 A61K31/34
A61P25/00 A61P11/06 A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	WO 99 52903 A (WARNER-LAMBERT COMPANY) 21 October 1999 (1999-10-21) page 3, line 25 -page 5, line 25	1-18
A	WO 98 07718 A (WARNER-LAMBERT COMPANY) 26 February 1998 (1998-02-26) page 2, line 13 -page 5, line 25	1-18
Y	WO 95 33744 A (WARNER-LAMBERT COMPANY) 14 December 1995 (1995-12-14) page 4, line 10 -page 10, line 26	1-18
Y	WO 95 14017 A (ELI LILLY AND COMPANY) 26 May 1995 (1995-05-26) page 3, line 10 -page 6, line 30	1-18
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 May 2000

Date of mailing of the international search report

18/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kyriakakou, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/29592

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 443 132 A (FUJISAWA PHARMACEUTICAL CO., LTD) 28 August 1991 (1991-08-28) page 3	1-18
Y	US 5 716 979 A (DAVID CHRISTOFFER HORWELL ET AL.) 10 February 1998 (1998-02-10) cited in the application column 2, line 30 -column 6, line 65	1-18
Y	US 5 594 022 A (DAVID C. HORWELL ET AL.) 14 January 1997 (1997-01-14) column 2, line 21 -column 6, line 51	1-18
Y	HONGBO QI ET AL.: "L-TRYPTOPHAN UREA AMIDES AS NK1/NK2 DUAL ANTAGONISTS" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, 1998, pages 2259-2262, XP004137257 the whole document	1-18
Y	DAVID C. HORWELL ET AL.: "quantitative Structure-Activity relationships (QSARs) of N-terminus Fragments of NK1 tachykinin Antagonists: A comparison of Classical QSARs and three-Dimensional QSARs from Similarity Matrices" J. MED. CHEM., vol. 38, no. 22, 1995, pages 4454-4462, XP002041962 the whole document	1-18
Y	SOLO GOLDSTEIN ET AL.: "Bioactive conformations of peptides and mimetics as milestones in drug design: Investigation of NK1 receptor antagonists" LETTERS IN PEPTIDE SCIENCE, vol. 2, 1995, pages 125-134, XP000650996 the whole document	1-18

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 29592

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 11-18
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 11-18
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte Jonal Application No

PCT/US 99/29592

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9952903 A	21-10-1999	AU 3011499 A	01-11-1999
WO 9807718 A	26-02-1998	AU 4146697 A EP 0920424 A NO 990788 A PL 331710 A	06-03-1998 09-06-1999 19-02-1999 02-08-1999
WO 9533744 A	14-12-1995	AU 693898 B AU 2595095 A CA 2187531 A EP 0764163 A JP 10501228 T NZ 287284 A US 5610176 A ZA 9504609 A	09-07-1998 04-01-1996 14-12-1995 26-03-1997 03-02-1998 28-10-1998 11-03-1997 26-01-1996
WO 9514017 A	26-05-1995	AU 1098895 A AU 9725598 A CA 2176735 A CN 1141043 A CZ 9601410 A EP 0729468 A FI 962074 A HU 76269 A JP 9505304 T NO 962012 A NZ 276638 A PL 314487 A SG 52654 A US 5670499 A US 5684033 A ZA 9408926 A	06-06-1995 25-02-1999 26-05-1995 22-01-1997 11-12-1996 04-09-1996 15-05-1996 28-07-1997 27-05-1997 08-07-1996 28-07-1998 16-09-1996 28-09-1998 23-09-1997 04-11-1997 10-05-1996
EP 443132 A	28-08-1991	AT 98651 T AU 640185 B AU 6801090 A CA 2032864 A CN 1064080 A, B CN 1159949 A DE 69005286 D DE 69005286 T DK 443132 T ES 2060910 T FI 906204 A, B, HK 18696 A HU 56581 A HU 9500376 A IE 64570 B JP 2560919 B JP 4210996 A KR 180223 B NO 177535 B PT 96324 A, B RU 2055078 C US 5468731 A ZA 9009901 A	15-01-1994 19-08-1993 27-06-1991 23-06-1991 02-09-1992 24-09-1997 27-01-1994 21-04-1994 24-01-1994 01-12-1994 23-06-1991 09-02-1996 30-09-1991 28-08-1995 23-08-1995 04-12-1996 03-08-1992 01-04-1999 26-06-1995 30-09-1991 27-02-1996 21-11-1995 30-10-1991
US 5716979 A	10-02-1998	US 5594022 A	14-01-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/US 99/29592

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5716979 A		US 5981755 A	09-11-1999
		US 5856354 A	05-01-1999
		AU 687754 B	05-03-1998
		AU 5005593 A	15-03-1994
		EP 0655055 A	31-05-1995
		JP 8500361 T	16-01-1996
		NZ 255721 A	24-06-1997
		WO 9404494 A	03-03-1994
US 5594022 A	14-01-1997	US 5981755 A	09-11-1999
		US 5716979 A	10-02-1998
		US 5856354 A	05-01-1999
		AU 687754 B	05-03-1998
		AU 5005593 A	15-03-1994
		EP 0655055 A	31-05-1995
		JP 8500361 T	16-01-1996
		NZ 255721 A	24-06-1997
		WO 9404494 A	03-03-1994

This Page Blank (uspto)